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Aims of present study 
The overall interest in Professor Danbolt’s research group at the Department of 
Anatomy, University of Oslo, is the control of neurotransmitter concentrations and 
diffusion in the extracellular space in between synapses in the central nervous system. 
My research has focused on the transporter proteins moving the transmitter amino acids 
(GABA and glutamate) across cell membranes, and on the roles of these transporter 
proteins in normal brain physiology and temporal lobe epilepsy. Changes in transporter 
function and expression have been reported in all neurological diseases, and these 
changes appear to be part of the pathogenetic processes ultimately leading to nerve cell 
damage and neurological and psychological disabilities (for review see: Danbolt, 2001).  
In 1999 I applied for a summer research scholarship that was announced by the 
Norwegian Research Council. Professor Jon Storm-Mathisen at the Department of 
Anatomy was my lecturer and I had talked to him about starting research. I did not get the 
scholarship, but Professor Storm-Mathisen wanted students in his lab and he gave me 
economic compensation for doing research in his lab that summer. My project was to 
study changes in expression of glutamate and GABA transporters in rat brain after 
injection of amphetamine. For an inexperienced researcher like me it turned out to be a 
project way over my head, but that summer I really got a good introduction to basic lab 
techniques.  
After that summer I started to work as a Medical Student Research Fellow under 
Professor Niels Chr. Danbolt and gradually during my year at Medical School I felt more 
competent as a researcher. I have contributed on different projects that involved 
transporter expression after immobilization stress, corticosterone injections (see abstract 
1), and worked on developing an ELISA procedure using a robot. The results form the 
immobilization stress project was presented as a poster on the International Society for 
Neurochemistry 18th Biennial Meeting, Buenos Aires, Argentina, and the ELISA 
procedure was later used to test antibody specificity (Paper 2). My main project at 
Professor Danbolt’s lab was later localization and quantification of the two GABA 
transporters in the rat brain (unpublished). This research project is in collaboration with 
Prof. D. Furness form Keele, UK.  
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I was later enrolled in the Medical Research Curriculum and because Professor 
Danbolt was collaborating with a lab at Yale University School of Medicine I got the 
opportunity to spend almost a year in USA doing research. I did my research at Professor 
de Lanerolle’s lab at Yale School of Medicine and had Dr. Tore Eid as my supervisor. 
The main goal in this lab is to investigate proteins and enzymes in hippocampus that are 
involved in temporal lobe epilepsy. Because the lab is affiliated with the internationally 
recognized The Epilepsy Surgery Program at Yale-New Haven Hospital, we had access 
to hippocampus tissue from patients with mesial temporal lobe epilepsy.  
Since high extracellular glutamate concentrations have been identified as a likely 
trigger of epileptic seizures in mesial temporal lobe epilepsy (MTLE), it was a good 
opportunity to investigate if these high glutamate levels could be the result of down-
regulation of glutamate transporters (paper 1).  
I addition to my main project I worked on two other project at Yale involving the 
human epileptic hippocampus. I looked at perivascular expression of aquaporin 4 (AQP4) 
using electron microscopy (paper 3) and investigated the distribution of GABA 
transporters (GAT1 and GAT3) using immunohistochemistry, Western blotting and 
electron microscopy (unpublished). 
Overall my research has involved GABA or glutamate transporter proteins in 
normal brain physiology and temporal lobe epilepsy. I have learned and used techniques 
like membrane protein purification, confocal imaging, electron microscopy, Western 
blotting, antibody production, and immunohistochemistry. In addition to using rats, 
human tissue from epileptic patients has given me more clinical knowledge. It is after all 
patients that bring research to life. Research has given me an appreciation and enthusiasm 
for problem solving and basic science and I intend to continue research activity 
throughout my career, applying these skills to my work in the clinic. 
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Papers  
Abstract 1 
 
Comments on abstract 1 
 
Beckstrøm, H. // Bjørnsen, L. P. // Arancibia, S. // Tapia-Arancibia, L. // Danbolt, N. C. 
- Immobilization stress increases the hippocampal protein levels of the GABA transporter 
GAT1-Journal of Neurochemistry-2001-78-Supplement: 1- p. 37-Abstract 
 
 This was a project where I collaborated with Dr. Henning Beckstrøm to 
investigate changes in GABA, glycine, and glutamate transporters during stress. I was 
responsible for carrying out the part of the project that involved corticosterone-21-
acetate. I injected the corticosterone into the rats, prepared the rat brain tissue, and 
performed the Western blot analysis. I also visited our colleagues S. Aranicibia and L. 
 - 8 -  
Tapia-Arncibia at Laboratoire de Plasticité, Univeristé de Montpellier, Montpellier, 
France, to pick up tissue samples for the project. The immobilization stress was 
performed using special restraining devices in France.  
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Paper 1 
Glial Glutamate Transporters in Human Epileptogenic Hippocampus 
 
LP Bjørnsen 3, T Eid1,2, S Holmseth3, NC Danbolt3, D.D. Spencer1, NC de Lanerolle1 
1 Department of Neurosurgery and 2 Laboratory Medicine, Yale University School of Medicine, New Haven, 
Connecticut, USA; 3 CMBN at Department of Anatomy, Institute of Basic Medical Sciences, University of Oslo, 
Blindern, Norway 
 
Corresponding author: Dr. Nihal C. de Lanerolle, Department of Neurosurgery FMB414, Yale University School of Medicine, 
333 Cedar Street, New Haven, Connecticut 06520-8082, USA. Tel: 203-785-3258, Fax: 203-737-2159, email: 
nihal.delanerolle@yale.edu 
 
Abstract  
Glutamate is the major excitatory neurotransmitter in 
the brain and is implicated in the pathogenesis of 
neurodegenerative diseases. High extracellular 
glutamate concentrations have been identified as a 
likely trigger of epileptic seizures in mesial temporal 
lobe epilepsy (MTLE), and these high glutamate levels 
could be the result of malfunctioning and /or down-
regulation of glutamate transporters. Five glutamate 
transporters have been cloned and are responsible for 
the removal of potentially excitotoxic excess glutamate 
from the extracellular space. This study aimed to 
investigate the differences in distribution of the two 
glial glutamate transporters that are predominantly 
responsible for removal of synatically released 
glutamate, in hippocampal seizure foci with and 
without sclerosis. The distribution of EAAT1 
(GLAST) and EAAT2 (GLT) in hippocampi of 
patients with medically intractable temporal lobe 
epilepsy was studied by means of 
immunohistochemistry, electron microscopy and 
Western blotting. Western blotting showed no 
significant differences between non-sclerotic and 
sclerotic hippocampi for both EAAT1 and EAAT2. 
Immunocytochemistry only detected EAAT1 and 
EAAT2 in astrocytes in non-sclerotic and sclerotic 
hippocampi. There was weaker immunoreactivity for 
both glutamate transporters in areas associated with 
neuronal loss, especially in CA1. In areas with less 
pronounced neuronal loss, like CA2, subiculum and 
parts of the dentate ML, showed no decrease and even 
an apparent increase in immunoreactivity. Such 
compensatory changes in immunoreactivity may 
account of the lack of differences between the groups 
in immunoblot studies because the blots shows the 
average concentrations in the samples. These data 
suggest that differences in glial glutamate transporter 
distribution between the two groups of hippocampi 
may be an insufficient explanation for the high levels 
of extracellular glutamate in sclerotic seizure foci 
observed in in vivo dialysis studies. 
 
Keywords: Astrocytes, Glutamate, Hippocampus, 
Temporal Lobe Epilepsy, MTLE, EAAT, GLAST, 
GLT 
 
Introduction  
Glutamate has long been thought to play a major role in 
the initiation and spread of seizure activity (Meldrum, 
1994). Animal studies have shown that the administration 
to the hippocampus of glutamate or glutamate analogues 
triggers seizures, while co-injection of glutamate 
antagonists blocks the seizures (Olney JW., 1978; Olney 
et al, 1986). 
Temporal lobe epilepsy (TLE) is among the 
most common of the chronic seizure disorders (Hauser et 
al., 1975), and since this form of epilepsy is often 
intractable (Chadwick D., 1990) many of these patients 
undergo anteromedial temporal lobectomy with 
hippocampectomy for seizure control (Spencer et al., 
1984). Approximately 70% of the resected hippocampi 
are characterized by pronounced neuronal loss and 
astroglial proliferation, especially in areas CA1, CA3 and 
the dentate hilus (de Lanerolle et al., 1994). These 
neuropathological features are the hallmarks of 
hippocampal sclerosis, a distinctive characteristic of 
patients with mesial temporal lobe epilepsy (MTLE) 
(Sommer W., 1880). Hippocampal sclerosis is believed to 
play a key-role in the generation of seizures in MTLE 
(Mathern et al., 1997; de Lanerolle and Lee, 2005).  
In the sclerotic hippocampus changes in 
NMDA and AMPA receptors have been observed (de 
Lanerolle et al., 1998; Musshoff et al., 2000) and 
intracellular recordings from dentate granule cells in the 
human MTLE hippocampus have revealed a glutamate 
dependent hyperexcitability in these neurons (Williamson 
A, 1994). Elevated levels of extracellular glutamate are 
observed in patients with various epilepsies (e.g. Janjua et 
al., 1992; Ferrie et al., 1999) and in vivo microdialysis 
studies of patients with MTLE have shown that the 
extracellular concentration of glutamate rises in sclerotic 
hippocampi just before a seizure and remains high for at 
least 15 minutes after the cessation of electrographic 
seizure activity (During and Spencer, 1993). These results 
indicate that there may be an impaired glutamate uptake 
capacity and thus possible malfunctioning and/or down-
regulation of glutamate transporters (Meldrum et al., 
1999). 
Synaptically released glutamate is normally 
taken up by astrocytes and rapidly converted to the 
nonexcitotoxic amino acid glutamine (Broman et al., 
2000). The glutamate uptake system (for review see 
Danbolt, 2001) consists of at five different transporter 
proteins and represents the only mechanism for removal 
of glutamate from the extracellular fluid in the brain. Five 
different glutamate (excitatory amino acid) transporters 
have been identified: EAAT1 (GLAST) (Storck et al., 
1992; Tanaka, 1993), EAAT2 (GLT) (Pines et al., 1992), 
EAAT3 (EAAC1)  (Kanai and Hediger, 1992), EAAT4 
(Fairman et al., 1995), and EAAT5 (Arriza et al., 1997). 
EAAT1 and EAAT2 are expressed by astrocytes (Danbolt 
et al., 1992; Levy et al., 1993; Chaudhry et al., 1995; 
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Lehre et al., 1995), while EAAT3 is neuronal and 
probably predominantly postsynaptic (Rothstein et al., 
1994). EAAT4 is a neuronal postsynaptic glutamate 
transporter in Purkinje cell spines (Yamada et al., 1996; 
Nagao et al., 1997; Dehnes et al., 1998) and EAAT5 is 
primarily expressed in the retina (Arriza et al., 1997). 
Although both neurons and glia contain glutamate 
transporters, it is generally accepted that more than 90 % 
of the forebrain glutamate uptake activity is mediated by 
EAAT2 (Danbolt et al., 1992; Haugeto et al., 1996; 
Tanaka et al., 1997; For review and discussion see 
Danbolt 2001) (). 
Reduced expression of glutamate transporters 
has been shown to cause or be associated with seizures in 
animal models. A relationship between glutamate 
transporter dysfunction and epilepsy was established by 
Tanaka and colleagues, who found that mutant mice 
lacking EAAT2 had increased extracellular glutamate 
levels and developed spontaneous seizures (Tanaka et al., 
1997). Several studies on animal models have later linked 
glutamate transporter expression and epilepsy, but the 
results of these studies have been contradictory. The 
majority show a decrease in EAAT1 and EAAT2 mRNA 
and protein (e.g. Samuelsson et al., 2000; Ueda et al., 
2001; Ingram et al., 2001), and an increase in EAAT3 
mRNA and protein (e.g. Ghijsen et al., 1999; Ueda et al., 
2001; Crino et al., 2002;Gorter et al., 2002) in animal 
epileptic models. Some have on the other hand found an 
increase in EAAT1 mRNA (Nonaka et al., 1998) and 
decreased EAAT3 mRNA (Akbar et al., 1998), while 
Simantov et al. found a down-regulation of EAAT3 and a 
modest increase in expression of EAAT2 in restricted 
hippocampal regions (Simantov et al., 1999). 
There are a few studies reporting on glutamate 
transporters in human epileptic patients. Tessler and 
colleagues (Tessler et al., 1999) found no change in the 
level of the mRNA or protein, by using in situ 
hybridization and Western blotting techniques 
respectively, for EAAT1 and EAAT2 in hippocampus 
and temporal cortex in temporal lobe epilepsy (TLE) 
patients compared to post mortem controls. In a study by 
Mathern and colleagues using immunocytochemical 
methods coupled with neuronal counting and image 
analysis, no changes in EAAT1 immunoreactivity (IR) 
were observed in hippocampi from TLE patients with 
hippocampal sclerosis compared with TLE patients 
without hippocampal sclerosis. Decreased EAAT2-IR 
was, in the same study, associated with neuronal loss. An 
increased EAAT3-IR was seen in areas where neurons 
were spared and a decrease in areas with neuronal loss 
(Mathern et al., 1999). A recent study from Proper et al. 
showed a general decrease in EAAT1-IR and EAAT2-IR 
in the sclerotic hippocampus when compared with the 
non-sclerotic hippocampus or post mortem controls 
(Proper et al., 2002). This decrease was accompanied by 
a decrease in mRNA levels for both transporters. An 
increase in neuronal EAAT3 protein levels in the resistant 
areas (CA2, granule cell layer and subiculum) in the 
hippocampal sclerosis group was also observed. Using 
immmunohistochemistry and quantitative western blots 
Eid et al. found no difference in EAAT2 expression 
between non-MTLE and MTLE hippocampi (Eid et al., 
2004). 
The aim of the present study is to further 
explore the differences in glial glutamate transporter 
distribution in the hippocampus between non-sclerotic 
and sclerotic hippocampi in TLE patients. The two glial 
transporters (EAAT1 and EAAT2) were studied by 
immunoblotting, immunohistochemistry and electron 
microscopic methods. 
 
Methods  
Patient Tissue  
Patients with medically intractable temporal lobe epilepsy 
underwent phased presurgical evaluation at the Yale-New 
Haven Hospital, and appropriate candidates underwent 
anteromedial temporal lobectomy with hippocampectomy 
according to standard procedures (Spencer DD, 1984). 
Informed consent from each patient and institutional 
approval were obtained for the use of tissue in this 
project. The surgically resected hippocampi were 
classified into two groups: (1) mesial temporal lobe 
epilepsy (MTLE) and (2) non-MTLE as described by Eid 
et al. (Eid et al., 2004). The MTLE hippocampus was 
characterized by pronounced neuronal loss (>50%) and 
extensive astroglial proliferation most pronounced in the 
hippocampal subfields CA1, CA3, and hilus (Kim JH, 
2001). Reorganization of peptidergic neurons (neurons 
containing dynorphin, somatostatin, neuropeptide Y, and 
substance P) in the dentate gyrus was also seen (de 
Lanerolle et al., 1994). On the other hand the non-MTLE 
hippocampi were recognized by a modest (<25%) 
neuronal loss throughout all hippocampal subfields, 
minimal astroglial proliferation, and no reorganization of 
peptidergic neurons in the dentate gyrus (Kim JH, 2001). 
They were obtained from patients with a mass lesion in 
the temporal lobe outside the hippocampus (MaTLE) and 
those with no clear etiology, described previously as 
paradoxical temporal lobe epilepsy –PTLE (de Lanerolle 
et al., 1997). 
Tissue preparation  
Immediately after surgical resection two 5 mm thick 
slices were cut from the mid-portion of the hippocampus. 
One of the samples was immersed into a fixative 
containing 4 % formaldehyde and 15 % (v/v) of a 
saturated picric acid solution in 0.1 M phosphate buffer 
pH 7.4 (PB) for 1 hour, followed by immersion into 5 % 
acrolein in PB for 3 hours. Thereafter the tissue was 
rinsed and stored in PB at 4 °C. Fifty-micrometer coronal 
sections were cut on a Vibratome and processed for 
immunohistochemistry. The other sample was rapidly 
frozen on dry ice, stored at –80 °C, and later used for 
Western blots. 
Hippocampal Nomenclature  
The mesial temporal lobe consists of the hippocampus, 
parahippocampal gyrus, entorhinal cortex and amygdala. 
The hippocampus is commonly divided into the 
subiculum, Ammon’s horn and dentate gyrus (Lorente de 
Nó R., 1934). The Ammon’s horn is further subdivided 
into the areas CA1, CA2 and CA3, while the dentate 
gyrus is subdivided into the hilus, granule cell layer and 
molecular layer (Amaral and Insauti, 1990). 
 
Antisera and chemicals  
Antibodies against GLAST and GLT were prepared by 
immunizing rabbits with synthetic peptides (A522-541 
(PYQLIAQDNEPEKPVADSET) for GLAST and B563-
573 (SVEEEPWKREK) for GLT) coupled to keyhole 
limpet hemocyanin with glutaraldehyde (Lehre et al., 
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1995; Danbolt et al., 1998). The corresponding anti-
peptide antibodies were referred to as anti-A522 (rabbit 
8D0161; Ab,314) and anti-B563 (rabbit 1B0707; 
Ab,355). These antibodies were tested and characterized 
by Western blotting (Fig. 1) and immunohistochemical 
methods, and cross-reacted with human GLAST and 
GLT, respectively. Unless otherwise specified, all other 
chemicals were obtained from Sigma-Aldrich (St. Louis, 
MO).  
 
Immunohistochemistry and electron microscopy  
Vibratome sections were incubated free-floating in anti-
A522 (200 ng/ml) or anti-B563 (200 ng / ml) antibodies 
for 24 hours (RT), and then processed according to the 
avidin-biotin peroxidase method (Hsu et al., 1981) using 
a commercially available kit (Vectastain Elite, Vector 
Laboratories, Burlingame, CA). Immunstained sections 
from each patient were mounted on slides, dehydrated 
and coverslipped for light microscopic analysis. Control 
sections incubated without the primary antibody or by 
replacing it with preimmune sera were not 
immunostained. Additional immunostained sections were 
processed for electron microscopy. After immunostaining 
as described above the sections were treated with 2 % 
osmium tetroxide in PB, stained en bloc with 2 % uranyl 
acetate in water, dehydrated and flat-embedded in 
Durcupan ACM. Sections were cut on an ultramicrotome, 
transferred to 500-mesh copper grids (Electron 
Microscopic Sciences, Fort Washington, PA, USA), 
contrast-stained with lead citrate and examined in a 
transmission electron microscope (Jeol 1200 EX II) at 60 
kV.  
 
Western blot Analysis  
Sections containing all hippocampal subregions were cut 
from frozen non-MTLE and MTLE specimens. The tissue 
was homogenized in 10 tissue volumes of SDS-
solubilization buffer (1 % SDS with 150 mM NaCl and 
10 mM PB pH 7.4, 5mM EDTA, and 1 mM PMSF) using 
a FastPrep® Instrument (Qbiogene, Inc., Ca) and the 
FastRNA® Pro Green Kit (Qbiogene, Inc., Ca). The 
homogenates were then incubated for 10 min and 
centrifuged (1000 x g, 10 min, 15°C). The supernatant 
solutions were stored at 80°C.  The sample protein 
concentrations were determined using BCA Protein 
Assay Kit (Pierce, #23227) and the determination was 
preformed according to manufacturer’s protocol. Bovine 
serum albumin (BSA) was used as standard and the 
spectrophotometer (GeneQuant pro, Amersham) was set 
to 562 nm. The extracts were then subjected to SDS-
PAGE (Laemmli, 1970) and electroblotted (Towbin et al., 
1979) to nitrocellulose (100v, 1h). The Protein 
homogenates were diluted to a final protein concentration 
of 2 mg/ml in a loading buffer (10 % sucrose, 2 % (w/v) 
SDS (pure C12; Pierce 28312), 0.001 % (w/v) 
bromophenol blue, 62.5 mM Tris-HCl pH 6.8, and 5% 2-
mercaptoethanol) and applied at different concentration 
on precast polyacrylamide gels (Criterion, 10% Tris-HCl, 
BIORAD). The gels were run (200V, 40 min) in 
CriterionTM Cell Electrophoresis Module (BIORAD). 
Immunostaining of blots was done as previously 
described (Lehre et al., 1995) at room temperature. The 
immunolabeling of the blots was preformed using 
Supersignal West Dura Extended Duration Substrate 
(Pierce, cat#34075). First the nitrocellulose blots were 
washed (1x1min) in TBST (150mM NaCl, 0.05% (v/v) 
Tween 20, 0.05% (w/v) sodium azide and 10mM Tris-
HCl pH 8), blocked (30 min) in TBST with 4 % (w/v) 
skimmed milk powder (Nestle, Carnation, instant nonfat 
dry milk), washed (1 x 1 min) with TBST and incubated 
(overnight) with primary antibodies (200 ng / ml anti-
A522 or 200 ng / ml anti-B563) in TBST with 1% BSA 
(Sigma A-7888) and 0.05% (w/v) sodium azide. The blots 
were washed (1x1 min and 3x5-10 min) in TBST without 
azide, incubated 1 hour with peroxidase conjugated 
(HRP-Conjugated) anti-rabbit IgG (Anti-rabbit IgG 
peroxidase conjugate, A-1949, Sigma, diluted 1:30000) in 
TBST with 4 % dry milk (without azide) on a shaker. The 
blots were incubated for 5 min in Supersignal Substrate 
according to manufacturers protocol (Pierce, Prod # 
34075), after they had been washed (1x1 min and 3x5-10 
min) with TBST (without azide). The blots were read at a 
Kodak Image 2000 R and the intensity of the bands was 
calculated for GLAST and GLT using the Kodak 
software. A standard curve was made with increasing 
concentrations of homogenized hippocampal tissue from 
a non-MTLE patient to determine the linear range and 3, 
6, and 12 µg protein were used from each patient. Both 
antibodies gave a strong single band consistent with the 
expected molecular mass of the glial glutamate 
transporters. Substitution of the primary antibodies with 
normal serum completely abolished the staining. The 
blots were assessed using a two-tailed Mann-Whitney U 
test (Statview Software, SAS Institute, NC).  
 
Results  
Clinical characteristics of patients  
The demographic and clinical characteristics of the 
patients used in this study were similar to those in a larger 
sample reported previously (de Lanerolle et al., 2003) 
(Table 1). Similar numbers of males and females were 
studied in the non-MTLE group, but the male:female 
relationship was 5:8 in the MTLE group. Eight of the 10 
non-MTLE hippocampi were of the PTLE category 
(Table 1). The ages at surgery of the patients in the 
MTLE group were not significantly different (MTLE 
mean 37 years ± 4 SEM and non-MTLE 26 years ± 5 
SEM, p = 0.082, Mann-Whitney U, two-tailed test). The 
duration of seizure history prior to surgery was also not 
significantly different (MTLE 27 ±2 and non-MTLE 19 
±4 years, p = 0.0585, Mann-Whitney U, two-tailed test). 
All MTLE patients had hippocampal sclerosis 
characterized by significant neuronal loss easily seen in 
area CA1 (neuronal counts not shown) compared to non-
MTLE. There was no difference between groups as 
regards the antiepileptic drugs they were on at the time of 
surgery.  
 
Western blotting  
Western blot studies of the transporters GLAST and GLT 
were carried out on whole hippocampal sections from 
non-MTLE and MTLE hippocampi to determine if there 
was an overall difference in the levels of these 
transporters between patient groups (figure 1). No 
statistically significant difference in the expression of 
GLAST and GLT between the non-MTLE and MTLE 
hippocampi was observed (GLAST: p = 0.27, GLT: p = 
0.95, Mann-Whitney U, two-tailed test). However, since 
such a result may also be produced in the face of regional 
changes in distribution, which may be compensatory, an 
immunohistochemical study of the distribution of GLAST 
and GLT was undertaken. 
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Cellular localization of GLAST and GLT 
 In both non-MTLE and MTLE hippocampi 
both EAAT1 and EAAT2 were localized to astrocytes, 
being seen in both somata and processes of these cells 
(Fig. 2D, 2E, 3D, 3E). The staining was around neurons 
sometimes outlining them (Fig. 2C-F, 3C-F). No neuronal 
labeling was detected.  
 At the ultrastructural level localization of 
EAAT1 and EAAT2 the immunoreactivity was studied in 
area CA1 of the hippocampus in both MTLE and non-
MTLE patients (Fig. 4). CA1 was chosen as sclerosis is 
most prominent in this area of the hippocampus. Only 
astrocytes were labeled, processes (Fig.4A) as well as 
somata. Labeled astrocytic processes could be seen to 
separate unlabeled pyramidal cell bodies and terminals 
(Fig. 4B, C, D). The immunostained somata contained the 
organelles typical for astrocytes. Though they were 
adjacent to strongly labeled astrocytic processes, the axon 
terminals themselves always appeared completely 
unlabeled (Fig. 4B, 4D). The labeling was entirely 
intracellular. In moderately reacted preparations the 
diaminobenzidine reaction product appeared concentrated 
close to the inner surface of the plasma membrane sparing 
the outer lamina (Fig 4E). The extracellular space always 
was free of reaction product. Fibrous astrocytes in white 
matter were also labeled (Fig. 4F). Strong 
immunolabeling for EAAT1 and EAAT2 was also seen at 
the endothelial-astrocyte interface with the labeling on the 
astrocyte membrane (Fig. 4E). Such labeling was seen in 
both non-MTLE and MTLE tissue. 
 
Regional distribution of immunolabeling 
 The pattern of immunolabeling for EAAT1 and 
EAAT2 in non-MTLE differed somewhat from the 
MTLE group. Overall, there was weaker EAAT1 than 
EAAT2 immunostaining. EAAT1 and EAAT2 were 
expressed in all subfields of both non-MTLE and MTLE 
hippocampi. The immunoreactivity was homogeneous 
and seen in all sublayers, but a patchy pattern, was seen in 
some subareas such as CA1 for both EAAT1 and EAAT2 
in non-MTLE and MTLE (Fig. 2A, 2B, 3A, 3B), as 
earlier described for GLT in post mortem material 
(Milton et al., 1997; Proper et al., 2002). 
Dentate gyrus and hilus  
 The staining of both GLAST and GLT was 
mainly around pyramidal cells in hilus (not shown) and 
granule cells (figure 2c-d and 3c-d), outlining the 
neurons, and individual labeled astrocyte cell bodies were 
seen in the dentate molecular layer and polymorphic layer 
(not shown) in both non-MTLE (Fig. 2C, 3C) and MTLE 
(Fig. 2D, 3D). In MTLE compared to non-MTLE a loss 
of GLAST immunoreactivity was visually observed 
throughout these two regions (Fig. 2B). The 
immunoreactivity for GLT in the molecular layer of  
MTLE hippocampi, was less uniform than in the non-
MTLE, with some regions of the molecular layer showing 
even stronger labeling (Fig. 3B).  
Some areas of the hilus in MTLE also retained 
EAAT1 and EAAT2 immunoreactivity and individual 
labeled astrocytes were seen in these resistant areas (not 
shown). Blood vessels were outlined by the 
immunostaining for both EAAT1 and EAAT2 in all 
hippocampi (Fig 2C, 2D, 3C, and 3D).  
Hippocampal area CA1  
 The CA1 region in the MTLE is clearly 
sclerotic and smaller in size then the non-MTLE 
hippocampus (Fig 2B, 3B). The staining of both EAAT1 
and EAAT2 were mainly around pyramidal cells in non-
MTLE (Fig 2E, 3E). The neurons were outlined, but not 
as clearly as around the granule cells. It was hard to 
distinguish individual astrocytes due to an intricate 
meshwork of labeling in stratum radiatum, stratum 
pyramidale, and stratum oriens in non-MTLE hippocampi 
(not shown). In the MTLE hippocampi, the intensity of 
immunoreactivity for both GLAST and GLT appeared 
reduced in astrocyte cell bodies compared the non-MTLE 
area CA1, and this was associated with the neuronal loss 
and astroglial proliferation in CA1 (Fig. 2F, 3F).  
Hippocampal area CA3, CA2 and subiculum  
 The immunostaining for both GLAST and 
GLT in these regions was also mainly in fine processes 
around pyramidal neurons, but individual astrocytes were 
seen in stratum radiatum, stratum oriens, and subiculum 
in both non-MTLE and MTLE (not shown). Blood 
vessels were outlined by the staining for both GLAST and 
GLT in both groups of hippocampi, specially pronounced 
in subiculum. In the MTLE hippocampi, weaker 
immunoreactivity for GLAST was apparent in CA3 and 
CA2, whereas for GLT no noticeable differences were 
observed. The subiculum did not show any loss of 
immunoreactivity for either transporter in either group of 
hippocampi (Fig. 2B, 3B). Individual astrocytes cell 
bodies labeled for GLAST and GLT were observed in 
MTLE. (not shown).  
White matter and alveus 
A few astrocytes labeled with GLAST and GLT were 
seen in alveus and the white matter in both non-MTLE 
and MTLE groups (not shown).  
 
Discussion 
In this study we demonstrate both at the light 
microscopic and ultrastructural level that in the human 
hippocampus both EAAT1 and EAAT2 are found in 
astrocytes. No immunoreativity for these two proteins 
was observed in neurons. This finding is fully consistent 
with the localization of EAAT1 and EAAT2 in the rat 
hippocampus (Lehre et al., 1995). In contrast, one study 
of the human hippocampus has reported EAAT2 mRNA 
in neurons as well. This has not been corroborated in the 
immunohistochemical studies by these same workers or 
by in situ hybridization or immunohistochemistry in any 
other studies (Lehre et al., 1995; Mathern et al., 1999; 
Tessler et al., 1999). 
Prior studies of the distribution of EAAT1 and 
EAAT2 in surgically removed human sclerotic 
hippocampi compared to non-sclerotic hippocampi have 
concluded that there is a reduction in EAAT2 (Proper et 
al., 2002; Mathern et al., 1999), a slight or no reduction 
in EAAT1 (Proper et al., 2002; Mathern et al., 1999) or 
essentially no-change in these transporters (Tessler et al., 
1999). The Western blot data presented in the current 
study suggests that there is no change in the levels of 
either EAAT1 or EAAT2, though immunohistochemical 
localization shows weaker staining in sclerotic regions 
like CA1 and the hilus compared to that in non-sclerotic 
hippocampi. This apparent discrepancy needs 
explanation. 
Careful perusal of previous reports of reduced 
astrocyte glutamate transporters in the sclerotic 
hippocampus from patients with TLE, show that the 
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actual evidence for such reduction is not compelling. 
Firstly the two studies that report a reduction of glutamate 
transporters, especially of EAAT2, do so on the basis of 
immunohistochemistry on fixed tissue (4% formaldehyde 
for 24 - 48 hr), whereas those that assessed transporter 
levels in parallel with immunoblots report no change 
(Tessler et al., 1999 and this study). It is well known that 
fixatives reduce the antigenicity of molecules and do not 
provide a reliable basis for quantification (Danbolt, 
2001).  
Evaluation of immunohistochemical data also 
presents further issues for discussion. The data presented 
in Proper et al (Proper et al., 2002) show that staining 
levels for EAAT1 quantified as a Relative Optical 
Density (ROD) measure show a reduction only for the 
dentate polymorphic layer (PML) in the sclerotic 
compared to the non-sclerotic hippocampus, despite the 
demonstration in their immunohistochemical 
photomicrographs of reductions in staining in area CA1 
and CA3/CA2 (see Fig. 2 Proper et al., 2002). Mathern et 
al (Mathern et al., 1999) also find no difference in 
EAAT1 immunostaining levels between sclerotic and 
non-sclerotic hippocampi. Thus in essence all previous 
studies concur with our data that there is no difference in 
EAAT1 levels. Comparisons that report reductions 
relative to autopsy controls must be interpreted with 
caution as postmortem changes are in general likely to 
results in changes of glutamate transporter levels due to 
autolytic effects (Beckstrøm et al., 1999).  
EAAT2 is the predominant glutamate 
transporter in the hippocampus (Danbolt et al., 1992; 
Haugeto et al., 1996; Tanaka et al., 1997; For review and 
discussion see Danbolt, 2001). Proper et al (Proper et al., 
2002) report on the basis of immunohistochemical 
staining that EAAT2 levels in areas CA1, CA2, CA3 and 
CA4 were reduced. Unlike for EAAT1, the 
immunohistochemical patterns and well as their ROD 
quantification are generally in concordance for EAAT2. 
However, in situ hybridization studies by the same group 
show no quantitative change in EAAT2 in areas CA1 and 
CA2 (Fig 6B Proper et al., 2002) between sclerotic and 
non-sclerotic hippocampi. Even though the granule cell 
layer in the sclerotic hippocampus appears visually to 
have a considerable reduction in mRNA (see Fig. 5F and 
5G Proper et al., 2002) no quantitative difference is 
recorded (Fig. 6B Proper et al., 2002). Thus the data for 
EAAT2 as presented in this study is equivocal at best. In 
a study using similar surgical tissue and patient types and 
fixed similar to that of the study by Proper et al., Mathern 
and co-workers found a reduction in EAAT2 only in the 
hilar area of sclerotic hippocampi (see Fig. 11 Mathern et 
al., 1999). No depletion of EAAT2 is shown for CA1 
either in gray value measures or immunoreactivity pattern 
shown in the illustrated figures (Fig 6E and F Mathern et 
al., 1999). Tessler et al (1999) also found no difference in 
EAAT2 levels between epileptic hippocampi and 
postmortem controls; this study did not distinguish 
between sclerotic and non-sclerotic hippocampi (Tessler 
et al., 1999). On the basis of these studies it would be 
reasonable to conclude that there is no appreciable 
difference in EAAT2 levels as well between sclerotic and 
non-sclerotic hippocampi. 
However, in the immunohistochemical 
localization studies shown in this paper as well as others, 
why does there appear to be reduced immunoreactivity in 
areas such as CA1 and the hilus in sclerotic hippocampi, 
while immunoblot analyses show no difference?  There 
are some possible explanations for this. The first may be 
that in areas such as CA1 where there is an apparent 
reduction in staining intensity, this may only be reflective 
of a redistribution of the transporter throughout the 
astrocytic processes in the sclerotic hippocampi rather 
than a true reduction in level. Evidence in support of this 
is that ultrastructural localization studies show EAAT2 
immunoreactivity throughout astrocytic process despite 
apparent loss suggestive in light microscopy (present 
study). Likewise confocal immunohistochmical studies 
reveal EAAT2 immunoreactivity throughout astrocyte 
processes, even though staining in somata is reduced (Eid 
et al., 2004). Such redistribution of EAAT2 transporter in 
epileptic surgical tissue has previously been suggested by 
others (Tessler et al., 1999). An alternative possibility is 
that there may be compensatory changes in the expression 
of transporters in its different regions. Such a possibility 
is recognized in suggestive upregulation of transporter in 
subiculum and molecular layer (our study) with the 
apparent down regulation in other areas. 
Previous studies of the distribution of 
glutamate transporters (Proper et al., 2002; Mathern et 
al., 1999) have postulated a reduction in glutamate 
transporters to explain the striking physiological 
observation that there are elevated levels of extracellular 
glutamate in the epileptogenic (sclerotic) hippocampus 
(During and Spencer, 1993; Cavus et al., 2005) during 
seizures. Our own findings, like those of Tessler et al. 
(Tessler et al., 1999) find little support for a role of 
glutamate transporters in this phenomenon.  
On the contrary, there are several plausible 
alternative explanations for such elevated extracellular 
glutamate levels. One possibility may be related to the 
down regulation of glutamine synthetase in astrocytes in 
sclerotic areas of the hippocampus, which has been 
argued as a possible cause (Eid et al., 2004). 
Alternatively, or in addition, increased levels of 
inflammatory factors such as interleukin 1β and 
chemokines in sclerotic hippocampi are now recognized 
as able to cause the release of glutamate from astrocytes, 
which may be the source of the increased glutamate (data 
reviewed in de Lanerolle and Lee, 2005). These 
mechanisms may be more pertinent to elevated 
extracellular glutamate in sclerotic seizure foci than 
alterations in transporter levels or their function and 
certainly merit further study. 
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Comments to Paper 2 
Holmseth, Silvia // Dehnes, Yvette // Bjørnsen, L.P. // Boulland, Jean Luc // Bergles, 
Dwight // Furness N David // Danbolt, Niels Chr.- Specificity of antibodies – unexpected 
crossreactivity of antibodies directed against the EAAT3 (EAAC) glutamate transporter, 
Special Issue Article, Neuroscience 
 
 Specific antibodies are essential tools for identifying individual proteins in 
complex biological samples. While generation of antibodies is often straight forward, 
determinations of the antibody specificity is not. In this paper we illustrate how 
complicated this can be by describing the production and characterization of antibodies of 
the excitatory amino acid transporter 3 (EAAT3) glutamate transporter. I contributed on 
this paper by working on the ELISA-procedure for antibody testing. The procedure was 
performed by a Tecan Genesis 200 Workstation robot that I programmed. The antibodies 
were tested for reactivity toward proteins present in high concentrations in axons. A 
strong and specific reaction to tubulin was observed, but no to any of the other proteins 
tested, including another abundant cytoskeletal protein, actin. This result indicated that 
the anti-C479 antibodies recognized both tubulin and EAAT3 despite of being affinity 
purified against the corresponding peptide. 
This paper show that not all antibodies to synthetic peptides recognize the native protein 
and that the specificity of an antibody is hard to predict. Unwanted reactivity can be 
highly specific and thereby hard to recognize.  
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An abnormal accumulation of extracellular K in the brain has been
implicated in the generation of seizures in patients with mesial
temporal lobe epilepsy (MTLE) and hippocampal sclerosis. Experi-
mental studies have shown that clearance of extracellular K is
compromised by removal of the perivascular pool of the water
channel aquaporin 4 (AQP4), suggesting that an efficient clearance
of K depends on a concomitant water flux through astrocyte
membranes. Therefore, we hypothesized that loss of perivascular
AQP4 might be involved in the pathogenesis of MTLE. Whereas
Western blot analysis showed an overall increase in AQP4 levels in
MTLE compared with non-MTLE hippocampi, quantitative Immu-
noGold electron microscopy revealed that the density of AQP4
along the perivascular membrane domain of astrocytes was re-
duced by 44% in area CA1 of MTLE vs. non-MTLE hippocampi. There
was no difference in the density of AQP4 on the astrocyte mem-
brane facing the neuropil. Because anchoring of AQP4 to the
perivascular astrocyte endfoot membrane depends on the dystro-
phin complex, the localization of the 71-kDa brain-specific isoform
of dystrophin was assessed by immunohistochemistry. In non-
MTLE hippocampus, dystrophin was preferentially localized near
blood vessels. However, in the MTLE hippocampus, the perivascu-
lar dystrophin was absent in sclerotic areas, suggesting that the
loss of perivascular AQP4 is secondary to a disruption of the
dystrophin complex. We postulate that the loss of perivascular
AQP4 in MTLE is likely to result in a perturbed flux of water through
astrocytes leading to an impaired buffering of extracellular K and
an increased propensity for seizures.
dystrophin  epilepsy  seizures  astrocytes
Mesial temporal lobe epilepsy (MTLE) is one of the com-monest forms of medically intractable epilepsies. MTLE is
characterized by seizures that originate from mediobasal tem-
poral lobe structures, particularly the hippocampus, and neuro-
surgical resection of the epileptogenic hippocampus is often used
to treat this disorder. The resected, epileptogenic hippocampus
inMTLE is typically indurated and atrophic and displays massive
loss of neurons along with astroglial changes, particularly in
areas CA1 and CA3 and the dentate hilus, a condition known as
hippocampal (or Ammon’s horn) sclerosis. Electrophysiological
recordings from MTLE hippocampi have demonstrated that
these hippocampi are hyperexcitable when compared with non-
sclerotic hippocampi from patients with other types of temporal
lobe epilepsy, such as mass associated temporal lobe epilepsy
(patients with an extrahippocampal mass lesion) or paradoxical
temporal lobe epilepsy (patients without a mass lesion and with
seizures of unknown etiology). A fundamental question that
remains to be resolved is why the MTLE hippocampus is
hyperexcitable.
Studies of MTLE patient hippocampi have shown that the K
buffering capacity is diminished when compared with non-
MTLE hippocampi (1). This decrease is most pronounced in
sclerotic areas of the hippocampus, such as CA1, where patch
clamp experiments have demonstrated impaired uptake of K
into astrocytes by means of inwardly rectifying K channels (2,
3). The sclerotic, MTLE hippocampus also exhibits increased T2
signal density on magnetic resonance imaging and higher than
normal apparent diffusion coefficient on diffusion-weighted
imaging, suggesting that water accumulates in this structure (4).
Moreover, the expression of mRNA for aquaporin 4 (AQP4) is
increased in area CA1 of MTLE hippocampi compared with
non-MTLE hippocampi (5).
Loss of AQP4 from the perivascular endfoot domain of
astrocytes is associated with reduced clearance of extracellular
K and increased severity of seizures in an animal model of
-syntrophin deletion (6). This and other studies (7, 8) suggest
that buffering of K by means of inwardly rectifying K channels
on astrocytes depends on a parallel f lux of water through the
plasma membrane of these cells. Under conditions of high
neuronal activity, K and water are taken up by the astrocyte
membrane facing the neuropil and siphoned into blood or
cerebrospinal f luid through the endfoot membrane (9). Thus, in
experimental models, a perturbation of the flux of K and water
exacerbates the potential for seizures. Here, we present data
suggesting that a similar mechanism may operate in the hip-
pocampus of patients with MTLE.
Materials and Methods
Tissue. Patients with medically intractable temporal lobe epilepsy
underwent phased presurgical evaluation at the Yale–New Ha-
ven Hospital, and those selected for surgery had their hippocam-
pus resected according to standard procedures (10). During the
period of July 1996 to February 2002, a total of 86 hippocampi
were resected. Twenty-four of these hippocampi were randomly
selected for the present study, and they are therefore represen-
tative of the patient population that undergoes surgery at Yale.
Informed consent from each patient and institutional approval
were obtained for the use of tissue in this project (see Table 1).
Classification. Tissue classification was carried out separately by
two investigators (T.E. and N.C.d.L.), and the samples were
encoded for further use. Thus, the investigators performing the
Western blots (M.J.T. and M.A.-M.) and quantitative electron
microscopy (L.P.B.) were unaware of the patient categories until
the experiments had been completed and the data were ready for
statistical analysis.
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The surgically resected hippocampi were classified into two
groups (see ref. 11 for details): MTLE (group 1) and non-MTLE
(group 2). In MTLE, the seizure activity is believed to originate
from the hippocampus based on noninvasive studies, depth,
andor subdural electrode recordings. The MTLE hippocampus
is characterized by pronounced neuronal loss (50%) and
extensive astroglial proliferation in the hippocampal subfields
CA1, CA3, and hilus. Also, this category shows reorganization
of peptidergic (dynorphin, somatostatin, neuropeptide Y, and
substance P) neurons in the dentate gyrus. The non-MTLE
hippocampi are recognized by a modest (25%) neuronal loss
throughout all hippocampal subfields, minimal astroglial prolif-
eration, and no reorganization of peptidergic neurons in the
dentate gyrus. The histological pattern in the non-MTLE hip-
pocampi is similar to that of autopsy hippocampi. In50% of the
non-MTLE hippocampi, the seizures are thought to originate
from a mass lesion (usually a tumor) outside the hippocampus
but within the temporal lobe territory. In the remaining cases, no
mass lesion is apparent and the hippocampi are selected for
resection based on intracranial recordings of seizure onset.
Tissue Preparation. Immediately after surgical resection, two
5-mm-thick slices were cut from the center portion of the
hippocampus. One of the samples was immersed into a fixative
containing 4% paraformaldehyde and 15% (volvol) saturated
picric acid in 0.1 M phosphate buffer, pH 7.4, for 1 h, followed
by immersion into 5% acrolein in phosphate buffer, pH 7.4, for
3 h. Fifty-micrometer coronal sections were cut on a Vibratome
and either (i) stored in a cryoprotection solution (FD Neuro-
Technologies, Catonsville, MD) at 80°C until processed for
preembedding immunohistochemistry or (ii) processed immedi-
ately for freeze substitution. The other sample was rapidly frozen
on dry ice and cut coronally into 200-m sections on a cryostat
and stored at 80°C until used for Western blotting.
Antisera and Chemicals. Affinity-purified polyclonal (rabbit) an-
tibodies against AQP4 (Chemicon) and monoclonal (mouse)
antibodies against dystrophin (NovoCastra, Newcastle upon
Tyne, U.K.) were used. The dystrophin antibody was made
against a synthetic polypeptide consisting of the last 17 aa of the
carboxyl terminus of the human dystrophin sequence (SSR-
GRNTPGKPMREDTM). This sequence is present in the as-
trocyte-specific form of dystrophin, Dp71 (12). Unless otherwise
specified, all other chemicals were obtained from Sigma–
Aldrich.
Western Blotting. Frozen non-MTLE and MTLE whole hip-
pocampi were sonicated on ice in homogenization buffer (50
Table 1. Characteristics of patients selected for the study
Case Gender
Age,
years
Years since first
unprovoked
seizure
AEDs at
surgery MRI findings Pathology Classification
1 M 39 16 ltg Unremarkable Unremarkable Non-MTLE
2 F 22 10 tpm Unremarkable Unremarkable Non-MTLE
3 F 46 28 cbz Unremarkable Unremarkable Non-MTLE
4 M 40 4 lev, vpa Unremarkable Unremarkable Non-MTLE
5 M 44 18 cbz, clo R hippocampal sclerosis Unremarkable Non-MTLE
6 F 49 42 lev Chiari I malformation; otherwise unremarkable Unremarkable Non-MTLE
7 F 38 30 cbz, tpm Unremarkable Unremarkable Non-MTLE
8 M 35 17 ltg, cbz Cavernous hemangioma, R amygdala, adjacent
to hippocampal head; normal hippocampus
Cavernous
hemangioma
Non-MTLE
9 M 27 1 cbz L mesial temporal lobe mass lesion encroaching
subbasal ganglia, replacing and involving
amygdala and anterior hippocampus
Oligodendroglioma Non-MTLE
10 F 10 5 ltg R temporal lobe tumor involving basal ganglia
and amygdala; bilateral hippocampal
atrophy.
Low-grade
astrocytoma
Non-MTLE
11 F 8 4 cbz L temporal lobe tumor Oligodendroglioma Non-MTLE
12 M 47 22 cbz R hippocampal atrophy Hippocampal sclerosis MTLE
13 F 36 14 cbz L hippocampal sclerosis Hippocampal sclerosis MTLE
14 F 45 27 cbz, pri, gpn R hippocampal atrophy Hippocampal sclerosis MTLE
15 M 40 39 cbz, pht Unremarkable Hippocampal sclerosis MTLE
16 M 27 26 gpn, flb R hippocampal atrophy Hippocampal sclerosis MTLE
17 M 24 16 tpm, pb R hippocampal atrophy Hippocampal sclerosis MTLE
18 F 28 19 cbz L hippocampal atrophy Hippocampal sclerosis MTLE
19 F 15 10 cbz, ltg L hippocampal sclerosis with increased signal
on FLAIR
Hippocampal sclerosis MTLE
20 F 50 40 cbz L hippocampal sclerosis with increased signal
on FLAIR; bilateral small vessel ischemic
changes
Hippocampal sclerosis MTLE
21 F 36 26 ltg, pri R hippocampal sclerosis with increased signal
on FLAIR
Hippocampal sclerosis MTLE
22 F 39 12 gpn, ltg R hippocampal sclerosis Hippocampal sclerosis MTLE
23 M 46 10 ltg, lev R hippocampal sclerosis Hippocampal sclerosis MTLE
24 F 51 33 cbz L hippocampal sclerosis Hippocampal sclerosis MTLE
For non-MTLE, n  11, and for MTLE, n  13. M, male; F, female; AEDs, antiepileptic drugs; cbz, carbamazepine; clo, clonazepam; flb, felbamate; pht,
phenytoin; lev, levetiracetam; li, lithium; ltg, lamotrigine; gpn, gabapentin; pb, phenobarbial; pri, primidone; tpm, topiramate; vpa, valproate; L, left; R, right;
FLAIR, fluid-attenuated inversion recovery imaging.
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mM 3-[N-morpholino]propane-sulfonic acidHCl2 mM DTT,
pH 7.63 mM EGTA0.5 mM magnesium acetate0.1 mM
sodium orthovanadate0.1 mM PMSF20 g/ml leupeptin10
g/ml pepstatin A5 g/ml aprotinin0.32 M sucrose). Protein
concentrations were determined with a BCA Protein Assay kit
(Pierce). After being diluted in a sample loading buffer (50%
sucrose7.5% SDS62.5 mM Tris, pH 6.82 mM EDTA3.1%
DTT0.01% bromophenol blue), 10 g of protein was added per
lane, separated by electrophoresis on 12% polyacrylamide gels
(MiniProtean II, Bio-Rad) and transferred onto poly(vinylidene
difluoride) membranes. Membranes were blocked for 1 h in
Tris-buffered saline (20 mM Tris137 mM NaCl, pH 7.6) plus
0.1% Tween 20 (TBS-T) plus 5% blocking agent [Enhanced
Chemifluorescence (ECH) kit, Amersham Biosciences], fol-
lowed by overnight incubation in primary antibody (1 gml
AQP4; catalog no. AB3068, Chemicon). Membranes were sub-
sequently incubated for 1 h in fluorescein-conjugated anti-rabbit
antibodies (ECF kit, diluted 1:600), followed by a 1-h incubation
in alkaline phosphatase-conjugated anti-f luorescein antibody
(ECF kit, diluted 1:2,500). All steps were carried out at room
temperature with antibodies diluted in TBST plus 1% milk
powder.
After each incubation, membranes were washed in TBS-T.
The chemifluorescent signal was detected with a laser scanner
(Molecular Imager FX, Bio-Rad). For each blot, a global
background subtraction was performed that removed the high-
frequency, low-intensity pixels. After magnification, individual
pixels were visible, and each band was traced manually by using
the same background pixel intensity immediately adjacent to the
band as a cutoff. Similarly, a standard curve was constructed for
each blot with increasing concentrations (within the linear range
of the curve) of SDS-homogenized human neocortex from a
non-MTLE patient, with the highest concentration set at 100%.
The volume values (volume  sum of intensities of the pixels
within the volume boundary  pixel area) of the bands were
determined for AQP4 and the relative concentrations from the
patient samples were determined by comparison with the stan-
dard curve.
Preembedding Immunohistochemistry for Light Microscopy. Vi-
bratome sections were processed free-floating according to the
avidin–biotin complex method of Hsu et al. (13) as described in
ref. 14 with the following modifications: Incubation in the
primary antibodies was done for 18 h at room temperature at
dilutions of 1:10,000 for anti-AQP4 and 1:5,000 for anti-
dystrophin; a commercially available kit (VECTASTAIN Elite,
Vector Laboratories) was used for the remaining procedure.
Freeze Substitution. Small tissue blocks (0.3  0.5  1 mm3) of
area CA1 were dissected from the 500-m Vibratome sections
and subjected to freeze substitution (15). Briefly, the tissue
blocks were cryoprotected in glycerol and rapidly frozen in liquid
propane at 190°C. The frozen tissue was immersed into
anhydrous methanol containing 0.5% uranyl acetate at90°C in
an automatic freeze substitution unit (EMAFS, Leica, Vienna,
Austria). The blocks were infiltrated with Lowicryl HM20 Resin
(Lowi, Waldkraiburg, Germany) at 30°C, polymerized by UV
light, sectioned at 60 nm, transferred to 500-mesh nickel grids,
and processed for ImmunoGold electron microscopy.
Postembedding ImmunoGold ElectronMicroscopy and Specificity Con-
trols. On-grid immunolabeling of AQP4 was carried out in six
non-MTLE and six MTLE cases according to the procedure of
Laake et al. (16) with some modifications. Briefly, the sections
were incubated for 2 h or overnight with the AQP4 antiserum
(raised in rabbit) diluted 1:100, followed by incubation for 2 h
with 10-nm colloidal gold-conjugated secondary antibodies to
rabbit IgG diluted 1:20 (EMGFAR, BB International, Cardiff,
Fig. 1. There is an overall increase in AQP4 protein in the MTLE hippocam-
pus. Western blots of representative non-MTLE and MTLE patient hippocampi
immunostained with antibodies against AQP4 reveal single bands at the
expected molecular mass of 32 kDa. The band intensities from six randomly
selected non-MTLE and MTLE hippocampi (total of 12) were determined and
visualized by box plots. The value of the y axis is the labeling intensity of AQP4
compared with a standard control of neocortical tissue (see Materials and
Methods for details). A 360% increase in labeling intensity for AQP4 is evident
in MTLE vs. non-MTLE (*, P  0.002, two-tailed Mann–Whitney U test).
Fig. 2. Although AQP4 is preferentially distributed around blood vessels in
the non-MTLE hippocampus, this localization is lost in MTLE. AQP4 is demon-
strated by preembedding immunohistochemistry on Vibratome sections of a
representative non-MTLE (A and D) and MTLE (B and C) hippocampus. (A) In
the non-MTLE hippocampus, immunoreactivity for AQP4 in the pyramidal
layer of Ammon’s horn (the area within the dashed line) is preferentially
distributed around blood capillaries. (Scale bar, 1 mm.) (D) This finding is
demonstrated in the high-power field of CA1, where the arrow indicates a
strongly immunopositive capillary amidst a weakly labeled neuropil. (Magni-
fication,6 selected portion of A.) (B) In the MTLE hippocampus, the prefer-
ential distribution of AQP4 around blood capillaries is lost in the pyramidal
layer in areas of sclerosis (such as CA1). Scale is the same as in A. (C) In the
high-power field of CA1 moderate immunolabeling for AQP4 is present
throughout the neuropil and also around blood capillaries, which are indi-
cated by arrows. (Magnification, 6 selected portion of B.)
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U.K.). The sections were counterstained with uranyl acetate
followed by lead citrate or lead nitrate before being examined in
a transmission electron microscope (Jeol EM 300). Substitution
of the primary antibodies with normal serum or preimmune sera
completely abolished the staining.
Statistical Analysis. A two-tailed Mann–Whitney U test was used
to examine the differences in the Western blot results. In the
postembedding experiments, gold particle densities were calcu-
lated per unit plasma membrane of randomly selected astrocyte
profiles that were facing (i) the perivascular compartment or (ii)
the neuropil. Gold particles were included in the counts as long
as they touched the membrane, even if their center of gravity
projected outside the plasma membrane. In addition, the total
number of gold particles per unit area was calculated from
particle counts in five randomly selected areas (total 60 m2)
of the neuropil from each patient. Analysis was performed on
electron micrographs that were digitized and analyzed by the
Neurolucida system (Microbrightfield, Burlington, VT). Gold
particle counts from six non-MTLE and six MTLE patients were
used in the analysis.
Results
The level of AQP4 protein in hippocampal specimens from six
non-MTLE and six MTLE patients was assessed by quantitative
Western blotting. AQP4 was elevated by 360% in MTLE than in
non-MTLE (P  0.002, two-tailed Mann–Whitney U test) (Fig.
1). This finding is in accord with RT-PCR experiments of patient
hippocampi in which the content of AQP4 mRNA is elevated by
257% in MTLE vs. non-MTLE (5). The increase in AQP4 in
MTLE is proportional to the increase in the astrocyte marker
glial fibrillary acidic protein (5); thus, the overall increase in
AQP4 in MTLE can be explained by the proliferation of
astrocytes typical of hippocampal sclerosis.
Immunocytochemistry was carried out to determine whether
the increase in AQP4 was associated with a subcellular redis-
tribution of AQP4. Light microscopic analysis revealed that
AQP4 was enriched near blood vessels in non-MTLE hip-
pocampi, consistent with a preferential localization of AQP4 in
the perivascular endfeet of astrocytes (n  11) (Fig. 2 A and D).
In CA1 of the MTLE hippocampus (n  13), the perivascular
localization of AQP4 was disrupted (Fig. 2 B and C). Detailed
analysis by ImmunoGold electronmicroscopy confirmed that the
AQP4 labeling was confined to the plasma membrane of astro-
cytes in non-MTLE (n  6) (Fig. 3) and MTLE (n  6)
hippocampi. Quantitation revealed that the labeling density was
reduced by 44% on the perivascular astrocyte membrane in
MTLE vs. non-MTLE (Fig. 3) hippocampi. In contrast, the
labeling density of the astrocyte membrane facing the neuropil
was the same in both patient categories. As expected from the
increased number of astrocyte profiles inMTLE the gold particle
density per unit area in randomly selected fields of the neuropil
was 173% higher in MTLE hippocampi than in non-MTLE
hippocampi (Fig. 3).
Anchoring of AQP4 to the perivascular astrocyte endfoot
membrane depends on interactions with proteins of the dystro-
Fig. 3. Quantitative ImmunoGold electron microscopy reveals significant loss of AQP4 from the perivascular astrocyte membrane in MTLE vs. non-MTLE
hippocampi. ImmunoGold electron microscopy of the endothelial–astrocyte interface in CA1 of a representative non-MTLE hippocampus demonstrates that
AQP4 (arrows) is enriched on the astrocyte membrane facing the endothelial cell. Considerably less labeling is present on the astrocyte membrane facing the
neuropil (arrowheads). (Inset) Quantitation of gold particle densities in random fields from area CA1 of six non-MTLE (n-MTLE) and six MTLE hippocampi. Gold
particle counts for MTLE are given as percent of non-MTLE SEM: astrocyte membranes facing the endothelial cell (cap; particles per m), 56 16% (*, P
0.01); astrocyte membranes facing the neuropil (cap; particles per m), no change. The number of gold particles per unit area of neuropil (particles per m2)
was 273  23% (**, P  0.013). A two-tailed Mann–Whitney U test was used for statistical analysis. bm, basal lamina; ns, not significant. (Scale bar, 100 nm.)
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phin complex (17). Notably, deficiency in either dystrophin (18)
or -syntrophin (6) leads to loss of perivascular AQP4. More-
over, patients with Becker muscular dystrophy, a disorder char-
acterized by defective expression of dystrophin, have increased
incidence of epilepsy (19). In a recent microarray analysis of
mRNA expression of nine dystrophin-associated proteins, only
dystrophin was significantly lower by 68% in MTLE vs. non-
MTLE hippocampi, whereas -syntrophin mRNA was un-
changed (5). To evaluate whether the deficiency of dystrophin in
MTLE is related to the redistribution of AQP4, we localized
dystrophin by immunohistochemistry with an antibody against
the carboxyl terminus of the molecule. This antibody recognizes
the 71-kDa major brain dystrophin isoform, Dp71, which is
expressed in astrocytes (20). In agreement with animal studies,
in the non-MTLE hippocampus, the immunolabeling for dys-
trophin was preferentially localized near blood vessels through-
out all hippocampal subfields (Fig. 4 A, C, and E). In the MTLE
hippocampus, the perivascular labeling for dystrophin was re-
duced in sclerotic areas (e.g., CA1) (Fig. 4 B, D, and F), despite
the presence of numerous blood vessels in the latter (data not
shown). In nonsclerotic areas of the MTLE hippocampus (Fig.
4 B and F), the labeling for dystrophin was similar to that of
non-MTLE hippocampi (Fig. 4 A and E).
Discussion
As pointed out in the Introduction, hippocampi removed from
patients with MTLE show evidence of an impaired water and K
homeostasis (1–3). This finding has obvious pathophysiological
implications, because any buildup of K in the extracellular
space would increase neuronal excitability and contribute to the
epileptogenicity of the relevant hippocampal subfields (21, 22).
A reduced capacity to handle excess K is likely to be particularly
deleterious once a seizure has been precipitated. In such a
situation a loss of K homeostasis could easily set up a vicious
cycle leading to a prolongation and aggravation of the epileptic
seizures (23).
According to experimental studies, the processes responsible
for clearance of extracellular K are compromised by removing
perivascular AQP4 (6). The most parsimonious interpretation of
the latter observation is that K homeostasis depends on the
integrity of the mechanisms that are responsible for water flux
through the perivascular astrocyte membrane. Functionally, the
perivascular membrane domain is coupled in series with the
astrocyte membrane domain that faces the neuropil and is likely
to be critically involved in mediating water and K efflux from
the extracellular space surrounding active synapses (6). Corrob-
orating the functional coupling between water transport and K
clearance, it has long been known that synaptic activation causes
not only an increase in extracellular K but also a decrease in
extracellular space volume (24, 25). The exact mechanism un-
derlying the coupling between K and water transport is not
known, but it has been proposed that the two transport processes
are coupled through the activation of glial bicarbonate uptake
(26). What is clear is that K is not fluxed through AQP4 itself
because AQP4 shows no evidence of a K conductance in
experimental models (27).
Mice lacking perivascular AQP4 after the removal of the
anchoring protein -syntrophin do not show any reduction in the
total level of AQP4 in brain tissue (28). Quantitative electron
microscopical studies have provided an explanation of this
finding: The loss of AQP4 from the perivascular membrane
domain is compensated for by a sustained or increased comple-
ment of AQP4 in the remainder of the astrocyte plasma mem-
brane (28). Our previous finding that the brains of these mice
display obvious deficiencies in water and K transport under-
lines the fact that astrocytes are functionally polarized and that
their normal function depends on a correct compartmentation of
their membrane molecules (6). Specifically, the mislocalization
of AQP4 induced by -syntrophin deletion interferes with
homeostatic processes that require a serial coupling between
endfeet and non-endfeet astrocyte plasma membranes (29).
The question addressed in the present study is whether
epileptogenic hippocampi from patients with MTLE display a
mislocalization of AQP4 similar to that found to be associated
with increased seizure vulnerability in transgenic mice. Our data
indeed show that MTLE tissue mimics tissue from syn/
animals by displaying a reduced density of AQP4 in perivascular
membranes. Moreover, as in syn/ animals, the tissue level of
AQP4 is not decreased but significantly increased.
The most pressing question is whether the changes observed
are responsible for the observed loss of K and water homeosta-
sis in the epileptogenic hippocampus. Extrapolation from the
transgenic studies discussed above suggests that such a mecha-
nistic coupling may exist. For obvious reasons this question
cannot be subjected to direct experimental testing. It should be
pointed out, however, that the present study provides the first
evidence that a perturbed expression pattern of a membrane
molecule could underlie the deficiency in water and K ho-
meostasis in MTLE. Whether other molecular mechanisms also
contribute will have to be resolved in future studies.
What could be themechanism underlying the loss of perivascular
AQP4 in MTLE hippocampi? That this loss reflects a general
depletion of AQP4 is ruled out by the finding that the tissue level
of AQP4 increases rather than decreases. It was logical to look for
changes in the dystrophin complex, which is known to be respon-
sible for anchoring of AQP4 at perivascular membranes (17).
Specifically, we tested whether tissue deficient in perivascular
AQP4 showed a concomitant loss of perivascular DP71, the major
dystrophin isoform in the brain (20). The finding that AQP4 and
DP71 were similarly mislocalized suggests that the loss of perivas-
Fig. 4. Loss of perivascular AQP4 in the MTLE hippocampus is associated with
a deficiency in perivascular dystrophin. Adjacent sections from the non-MTLE
(A, C, and E) and MTLE (B, D, and F) hippocampi shown in Fig. 1 were
immunolabeled with an antibody against the astrocyte-specific isoform of
dystrophin (Dp71) and counterstained with neutral red. (A and B) The low-
power micrographs from non-MTLE (A) and MTLE (B) depict the CA1-
subiculum-transition, with the pyramidal layer between the dashed lines.
(Scale bar, 500m.) (C,D, and E) In CA1 (C) and subiculum (E) of the non-MTLE
hippocampus, there is strong immunolabeling for dystrophin around blood
capillaries (arrows inCandE), whereas in the MTLE hippocampus, pericapillary
immunolabeling for dystrophin is reduced in CA1 (arrows inD). (Scale bars, 40
m.) (F) The validity of this finding is attested by the presence of numerous
strongly dystrophin-positive capillaries in the subiculum of MTLE. (Scale bar,
40 m.)
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cular AQP4 may be secondary to a dissolution of the dystrophin
complex. One possible mechanism underlying a dissolution of this
complex is activation of extracellular proteases (such as metal-
loproteinases) that could sever the coupling to the laminin of the
perivascular basal lamina that normally keeps the dystrophin
aquaporin complex in place (30, 31). Activation of extracellular
metalloproteinases is a common pathophysiological response e.g.,
to infections and stroke in the CNS (32).
Based on the present findings, we conclude that mislocaliza-
tion of AQP4 might contribute to the epileptogenicity of the
MTLE hippocampi. This conclusion does not necessarily mean
that the changes observed are primary events in the pathogenesis
of MTLE. It could well be that the mislocalization develops
rather late in the sequence of events that culminates in epilepsy.
However, the changes are not merely a trivial consequence of
gliosis, given that they are not reproduced in gliosis associated
with other pathological conditions (33). Irrespective of the
temporal course of events, our findings have identified a mo-
lecular mechanism that could be targeted pharmacologically to
reduce brain excitability.
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Comments to Paper 3 
This study suggest that loss of AQP4 may underlie deficient water and K+ 
homeostasis and contribute to the epileptogenicity of the MTLE hippocampi in humans. I 
performed the quantitative electron microscopy and made bar-plot in figure 3. In the 
postembedding experiments, gold particle densities were calculated per unit plasma 
membrane of randomly selected astrocyte profiles that were facing the perivascular 
compartment or the neuropil. Gold particles ere included in the counts as long as they 
touched the membrane, even if their center of gravity was projected outside the plasma 
membrane. In addition, the total number of gold particles per unit area was calculated 
from particle counts in five randomly selected areas (total ≈ 60 µm2) of the neuropil from 
each patient. Analysis was performed on electron micrographs that were digitized and 
analyzed. Gold particle counts from six non-MTLE and six MTLE patients were used in 
the analysis.  
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Focus of the thesis 
In this thesis I have chosen to focus on my work with glial glutamate transporters 
in the human epileptic hippocampus. I have contributed to other projects (see abstract 1, 
and Paper 2-3), but this is the project that I have been singly responsible for. I have done 
the research and writing on my own and feel that this project has given me the chance to 
be part of the whole research process; from idea to the finished product.  
Introduction 
Glutamate is the major excitatory neurotransmitter in the brain and is implicated 
in the pathogenesis of neurodegenerative diseases. High extracellular glutamate 
concentrations have been identified as a likely trigger of epileptic seizures in mesial 
temporal lobe epilepsy (MTLE), and these high glutamate levels could be the result of 
malfunctioning and /or down-regulation of glutamate transporters. The aim of the present 
study is to further explore the differences in glial glutamate transporter distribution in the 
hippocampus between non-sclerotic and sclerotic hippocampi in TLE patients. The two 
glial transporters (EAAT1 and EAAT2) were studied by immunoblotting, 
immunohistochemistry and electron microscopic methods. 
Glutamate  
The neurotransmitter glutamate mediates most of the excitatory (stimulating, 
activating) signals in the central nervous system. This does not only include signals 
involved in perception, cognition and movements, but also for cell survival, elimination, 
migration and differentiation, as well as for synapse formation and elimination (Fonnum, 
1984; Ottersen and Storm-Mathisen, 1984; Collingridge and Lester, 1989; Headley and 
Grillner, 1990). Further, glutamate affects brain energy consumption, free radical 
formation, cell volume and water transport. Glutamate has a role in the signal 
transduction in the nervous systems of apparently all complex living organisms, including 
man, and is considered to be the major mediator of excitatory signals in the mammalian 
central nervous system. From this it follows that glutamate has to be present in the right 
concentrations in the right places for the right time. Both too much and too little 
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glutamate is harmful. This implies that glutamate is both essential and highly toxic at the 
same time. 
Glutamate is one of the ordinary 20 amino acids which are used to make proteins 
and takes parts in typical metabolic functions like energy production and ammonia 
detoxification in addition to protein synthesis. Glutamate forwards its signaling function 
by binding to and thereby activating receptor on cells that are programmed to respond 
when exposed to glutamate. Several subtypes of glutamate receptors have been identified: 
NMDA, AMPA/kainate and metabotropic receptors (mGluR). Most of the nerve cells, 
and even glial cells, have glutamate receptors (Hösli and Hösli, 1993; Steinhauser and 
Gallo, 1996; Vernadakis, 1996; Conti et al., 1999; Shelton and McCarthy, 1999; Bergles 
et al., 2000). 
The normal concentration of glutamate in the extracellular fluid is low, in the 
order of a few micromolar. In contrast, the glutamate concentration inside the cells is 
several thousand times higher. The highest glutamate concentrations are found in nerve 
terminals (Storm-Mathisen et al., 1992; Ottersen et al., 1996) and the concentration inside 
synaptic vesicles may be as high as 100 millimolar. Glutamate is therefore almost 
exclusively located inside the cells and the intracellular location of some 99.99 % of 
brain glutamate is the reason why the huge amount of the transmitter is not toxic for the 
brain (Danbolt, 2001). This is essential because glutamate receptors can only be activated 
by glutamate binding to them from the outside. Hence, glutamate is relatively inactive as 
long as it is intracellular.  
There is uptake of glutamate into both glial cells and nerve terminals. Glutamate 
taken up by astroglial cells is converted to glutamine. Glutamine is inactive in the sense 
that it cannot activate glutamate receptors, and is released from the glial cells into to 
extracellular fluid. Nerve terminals take up glutamine and convert glutamine back to 
glutamate (Van den Berg and Garfinkel, 1971). This process is referred to as the 
glutamate-glutamine, and is important because it allows glutamate to be inactivated by 
glial cells and transported back to neurons in an inactive (non-toxic) form (Gjessing et al., 
1972; Hamberger et al., 1983; Hamberger and Nyström, 1984). 
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Fig. 1. The glutamate-glutamine cycle. This pathway represents a way of recycling transmitter glutamate. Glutamate 
released from a nerve terminal by exocytosis (which is ATP and Ca2 + dependent) is taken up by glutamate 
transporters present presynaptically (VI), postsynaptically (I) and extrasynaptically in astroglial cells (II). Astroglia 
detoxifies glutamate by converting it to glutamine in an ATP-dependent process. Glutamine is subsequently released 
from the glial cells by means of glutamine transporter (III) and taken up by neurons by means of other glutamine 
transporter (IV). Neurons convert glutamine back to glutamate. Synaptic vesicles are loaded with glutamate from 
cytosol by means of a vesicular glutamate transporter (V). 
 
Glutamate transporters 
Controlling the extracellular concentration of the neurotransmitter glutamate is 
crucial, but the mechanisms controlling glutamate are hard to study because glutamate is 
involved in so many different and interconnected processes. Evidence suggests that the 
control mechanisms of glutamate play key roles in the disease processes ultimately 
leading to the nerve cell damage, disabilities and suffering (for review see: Danbolt, 
2001).  
Synaptically released glutamate is normally taken up by astrocytes and, as 
mentioned, rapidly converted to the non-excitotoxic amino acid glutamine (Broman et al., 
2000). The glutamate uptake system (for review see Danbolt, 2001) consists of five 
different transporter proteins and represents the only (significant) mechanism for removal 
of glutamate from the extracellular fluid in the brain. Five different glutamate (excitatory 
amino acid) transporters have been identified: EAAT1 (GLAST) (Storck et al., 1992; 
Tanaka, 1993), EAAT2 (GLT) (Pines et al., 1992), EAAT3 (EAAC1) (Kanai and 
Hediger, 1992), EAAT4 (Fairman et al., 1995), and EAAT5 (Arriza et al., 1997). EAAT1 
and EAAT2 are expressed by astrocytes (Danbolt et al., 1992; Levy et al., 1993; 
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Chaudhry et al., 1995; Lehre et al., 1995), while EAAT3 is neuronal and probably 
predominantly postsynaptic (Rothstein et al., 1994). EAAT4 is a neuronal postsynaptic 
glutamate transporter in Purkinje cell spines (Yamada et al., 1996; Nagao et al., 1997; 
Dehnes et al., 1998) and EAAT5 is primarily expressed in the retina (Arriza et al., 1997). 
Although both neurons and glia contain glutamate transporters, it is generally accepted 
that more than 90 % of the forebrain glutamate uptake activity is mediated by EAAT2 
(Danbolt et al., 1992; Haugeto et al., 1996; Tanaka et al., 1997; For review and 
discussion see Danbolt 2001). 
The uptake process is driven by the electrochemical gradient across the cell 
membrane. Sodium is required for glutamate binding while potassium is required for net 
transport (Kanner and Sharon, 1978a; Roskoski, 1979; Barbour et al., 1988: Sarantis and 
Attwell, 1990: Szatkowski et al., 1991). The process is electrogenic (net positive charge 
moving in) and it is thereby stimulated by a negative membrane potential. The 
electrogenicity of the process implies that it generates a current, which can be measured 
with electrophysiological techniques. The transporters utilize the ion gradients of both 
sodium and potassium, and also H+ (Billups et al., 1996; Zerangue and Kavanaught, 
1996a; Levy et al., 1998b) as energy sources for the transport process. The EAAC and 
GLT glutamate transporters have the following stoichiometry: one glutamate is taken up 
together with three Na+ and one H+ in exchange for K+ (Zerangue and Kavanaught, 
1996a; Levy et al., 1998). In the only published study of the stoichiometry of GLAST 
(Klöckner et al., 1993) no conclusions were made concerning H+/OH-, but a 
stoichiometry of three Na+, one glutamate and one K+ was suggested.  
Localization of the glial transporter subtypes 
GLAST (EAATl) is expressed in astroglia throughout the central nervous system 
(Lehre et al., 1995; Chaudhry et al., 1995; Schmitt et al., 1997; Ullensvang et al., 1997). 
GLAST is present in all regions of the brain, with a relatively high level in the olfactory 
bulb, hippocampus, cerebral cortex and striatum, and lower concentrations in 
diencephalon and brainstem (Lehre et al., 1995). The GLAST protein concentration is 
particularly high in the Bergmann glia, in the molecular layer of cerebellum where it is 
the quantitatively dominating transporter (Lehre and Danbolt, 1998). 
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Fig. 2. Types of glutamate transporters at glutamatergic 
synapses. I. Glutamate transporters in glial cell plasma 
membranes, GLT and GLAST as well as some EAAC, 
remove glutamate from the extracellular fluid. This 
implies that they remove the glutamate that has already 
escaped from the synaptic cleft. GLT and EAAC pump 
one glutamate together with three Na+ and one H+ in to 
the cells in the exchange of one K+. GLT is the most 
abundant of the so far molecularly identified glutamate 
transporters. GLAST is, however, the major transporter in 
some regions, including cerebellum (molecular layer) and 
retina. II. Glutamate transporters are also found post 
synaptically in the plasma membranes of dendritic spines. 
These transporters, which include EAAT4 (only in 
cerebellar Purkinje cells) and EAAC (throughout the 
brain), have a relatively high associated CI- channel 
activity. III. The glutamate transporter in glutamatergic 
nerve terminals has still not been molecularly identified 
and the exact stoichiometry of the transport cycle is not 
known. Because it is reversal of this transporter that is 
responsible for release of most of the glutamate during 
ischemia and because the ease by which it reverses 
depends on the stoichiometry, precise information of the 
stoichiometry is important to obtain. IV. Synaptic 
vesicles are loaded with glutamate from cytosol by means 
of a glutamate transporter located in the plasma 
membrane of synaptic vesicles. The energy driving this 
transporter comes from the action of a vesicular Mg2+-
dependent ATPase in the vesicular membrane pumping 
H+ into the vesicles. V. Cystine, which is essential for the 
synthesis of glutathione (an important antioxidant), is 
transported into cells in exchange with glutamate. 
 
 
 
 
 
GLAST appears to be the quantitatively dominating glutamate transporter also in retina, 
where it is found in Müller cells and astrocytes (Derouiche and Rauen, 1995; Rauen et 
al., 1996; Lehre et al., 1997; Harada et al., 1998; Eliasof et al., 1998). There is a high 
degree of consistency between the localization of GLAST protein and GLAST mRNA as 
determined by immunoblotting, immunocytochemistry, and in situ hybridization. 
GLT (EAAT2) has only been found in astroglia in the normal postnatal and adult 
central nervous system (Danbolt et al., 1992; Levy et al., 1993; Rothstein et al., 1994; 
Lehre et al., 1995; Chaudhry et al., 1995; Schmitt et al., 1996; Ullensvang et al., 1997), 
with the exception of retina (Rauen and Kanner, 1994; Rauen et al., 1996; Harada et al., 
1998). It is the quantitatively dominating glutamate transporter in the forebrain (Lehre 
and Danbolt, 1998). It is found in the same astroglial cell membranes as GLAST (Lehre 
et al., 1995; Haugeto et al., 1996), and both GLT and GLAST are found at higher 
concentrations in the parts of the cell membranes facing neuropil (axons, nerve terminals, 
and small dendrites) than in membranes facing capillaries, pia, or large dendrites 
(Chaudhry et al., 1995). The regional distribution of GLT, however, is different from that 
of GLAST: The GLT concentration is highest in hippocampus, cerebral cortex and 
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striatum, with lower levels in diencephalon and mesencephalon, and only a low level in 
the olfactory bulb and cerebellum (Lehre et al., 1995). In spite of the exclusive astroglial 
localization, a clear GL T mRNA signal is also found in neurons in the adult brain, 
including pyramidal cells in hippocampus CA3 and pyramidal cells in the cerebral cortex 
(Torp et al., 1994; Schmitt et al., 1996; Torp et al., 1997; Berger and Hediger, 1998). 
Nevertheless, with these notable exceptions there is general consistency between the 
immunoblot data, immunocytochemistry, and in situ hybridization data for the regional 
distribution of GL T in the brain. Certain conditions apparently induce the expression of 
GLT protein in some neurons. This has been observed during prenatal development 
(Furuta et al., 1997a; Yamada et al., 1998; Northington et al., 1998), hypoxia (Martin et 
al., 1997), and in cell cultures (Mennerick et al., 1998; Brooks-Kaya1 et al., 1998). 
 
Fig. 3. Schematic representation of the detailed localization of glutamate transporters in the vicinity of the 
glutamatergic synapses. (A) Parallel fiber to Purkinje cell dendritic spine synapses in the cerebellar molecular layer. 
These synapses are completely surrounded by astroglial membranes containing GLAST and GLT at average densities 
of 4700 and 740 molecules per µm2 membrane, respectively (Lehre and Danbolt, 1998). The concentrations are highest 
towards neuropil and lower towards other structures like cell bodies, vascular endothelium, large dendrites and pia 
mater. EAAT4 is concentrated in the glia-covered parts of the membranes of Purkinje cell dendrites, highest at the 
spines and thinner dendrites. EAAC is present in Purkinje cell membrane as well as cytoplasm (Conti et al., 1998; 
Kugler and Schmitt, 1999), but quantitative data and information on the precise subcellular distribution of this are 
currently unavailable. (B) Glutamatergic synapse in the hippocampus (e.g. Schaffer collateral to pyramidal cell 
synapse). The synapses are only contacted and not surrounded by astroglia. GLT and GLAST are present in the 
astroglial membranes at average densities of 8500 and 2300 molecules per µm2 membrane, respectively, with highest 
concentration towards neuropil. Quantitative information is neither available on EAAC nor on the molecularly 
unidentified transporter in the glutamatergic nerve endings. 
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Temporal lobe epilepsy 
Although there are many types of epilepsy of both genetic and acquired forms, 
temporal lobe epilepsy (TLE) is among the most common of the chronic seizure disorders 
(Hauser et al., 1975; Engel et al., 2001), and the one most intensely studied. Temporal 
lobe epilepsy (TLE) was defined in 1985 by the International League Against Epilepsy 
(ILAE) as a condition characterized by recurrent unprovoked seizures originating from 
the medial or lateral temporal lobe. Despite a wealth of descriptive data obtained from 
patient histories, imaging techniques, electroencephalographic recording, depth recording 
before and during surgery, and from histological study of surgical and autopsy tissues, 
the epileptogenic process remains poorly understood.  
Patients with TLE exhibit neuronal loss and a network imbalance that presumably 
causes the clinical condition. It is believed that when the hippocampus is found to be 
asymmetrically atrophic on initial imaging (figure 4), the shrunken hippocampus is a 
likely source of epileptic seizures in TLE (Engel et al., 2001). The presence of a shrunken 
hippocampus is also a predictive indicator of the medically refractory state of the disease 
(Semah et al., 1998). Depth electrode recordings demonstrate hypersynchronous 
electrical activity in the hippocampus that is often associated with auras that can spread to 
cause clinical seizures (Engel et al., 2001). 
 
Figure 4 
Mesial temporal lobe epilepsy (MTLE). The EEG suggested a right temporal lobe focus. Coronal high-resolution T2-
weighted fast spin echo magnetic resonance image obtained through the body of the hippocampus demonstrates 
abnormal high signal intensity in the right hippocampus (white arrows; compare with the normal hippocampus on the 
left, black arrows) consistent with mesial temporal sclerosis (The McGraw-Hill Companies). 
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Since this form of epilepsy is often intractable (Chadwick, 1990) many of these 
patients undergo anteromedial temporal lobectomy with hippocampectomy for seizure 
control (Spencer et al., 1984). Approximately 70% of the resected hippocampi are 
characterized by pronounced neuronal loss and astroglial proliferation, especially in areas 
CA1, CA3 and the dentate hilus (de Lanerolle et al., 1994). The CA2 region is, on the 
other hand relatively spared. These neuropathological features are the hallmarks of 
hippocampal sclerosis, a distinctive characteristic of patients with mesial temporal lobe 
epilepsy (MTLE) (Sommer, 1880) (figure 5).  
 
 
Figure 5  
Photomicrographs of EAAT3 (EAAC)-like immunoreactivity in MTLE hippocampus. This low power view of the 
entire cross-section of a MTLE hippocampus shows the hallmarks of hippocampal sclerosis. The immunoreactivity is 
seen in the granule cell layer (GCL), molecular layer (ML), throughout the Ammon’s horn (CA4, CA3, CA2, CA1) in 
the pyramidal cells and subiculum. The hippocampus is characterized by pronounced neuronal loss in areas CA1, CA3 
and the dentate hilus (CA4), so there are less labeling in these regions. The CA2 region and subiculum are spared. Only 
neurons are labeled (granule cells and pyramidal cells). Pyr, stratum pyramidale; lm, lacunosum moleculare; alv, 
alveus; fim, fimbra. (LPB) 
 
Hippocampal sclerosis is believed to play a key-role in the generation of seizures 
in MTLE (Mathern et al., 1997; de Lanerolle and Lee, 2005), but we do not really know 
precisely which cell populations, when lost, cause the network imbalance in TLE, or 
which cells generate the seizure discharges. Nor do we have an effective drug treatment 
that both points to the identity of the defective component and corrects the network 
imbalance to an extent that produces symptomatic improvement (Sloviter, 2005).  
If the assumption that the hippocampus is a frequent source of seizures is correct, 
the observation that typical hippocampal sclerosis involves an extensive loss of dentate 
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hilar neurons and CA1 and CA3 pyramidal cells (Meldrum et al., 1992), logically focuses 
attention on surviving dentate granule cells (Tauck et al., 1985) and (Nadler et al., 2003) 
and subicular neurons (Cohen et al., 2002) as likely candidates for neurons that become 
the seizure generators. One perspective (“epileptogenic” mossy fiber sprouting) posits 
that a trauma- or seizure-induced loss of vulnerable dentate hilar neurons causes granule 
cells to redirect their axonal output to each other, resulting in a recurrent excitatory 
network (Tauck et al., 1985; Nadler et al., 2003). A second perspective (‘inhibitory’ 
mossy fiber sprouting) focuses on the postsynaptic targets of vulnerable hilar neurons, 
which include both granule cells and inhibitory neurons (Sloviter et al., 1992). 
Glutamate transporters in epilepsy 
Glutamate has long been thought to play a major role in the initiation and spread 
of seizure activity (Meldrum, 1994). Animal studies have shown that the administration 
to the hippocampus of glutamate or glutamate analogues triggers seizures, while co-
injection of glutamate antagonists blocks the seizures (Olney JW., 1978; Olney et al, 
1986). 
In the sclerotic hippocampus changes in NMDA and AMPA receptors have been 
observed (de Lanerolle et al., 1998; Musshoff et al., 2000) and intracellular recordings 
from dentate granule cells in the human MTLE hippocampus have revealed a glutamate 
dependent hyperexcitability in these neurons (Williamson, 1995). Elevated levels of 
extracellular glutamate are observed in patients with various epilepsies (e.g. Janjua et al., 
1992; Ferrie et al., 1999) and in vivo microdialysis studies of patients with MTLE have 
shown that the extracellular concentration of glutamate rises in sclerotic hippocampi just 
before a seizure and remains high for at least 15 minutes after the cessation of 
electrographic seizure activity (During and Spencer, 1993). These results indicate that 
there may be an impaired glutamate uptake capacity and thus possible malfunctioning 
and/or down-regulation of glutamate transporters (Meldrum et al., 1999). 
Reduced expression of glutamate transporters has been shown to cause or be 
associated with seizures in animal models. A relationship between glutamate transporter 
dysfunction and epilepsy was established by Tanaka and colleagues, who found that 
mutant mice lacking EAAT2 had increased extracellular glutamate levels and developed 
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spontaneous seizures (Tanaka et al., 1997). Several studies on animal models have later 
linked glutamate transporter expression and epilepsy, but the results of these studies have 
been contradictory. The majority show a decrease in EAAT1 and EAAT2 mRNA and 
protein (e.g. Samuelsson et al., 2000; Ueda et al., 2001; Ingram et al., 2001), and an 
increase in EAAT3 mRNA and protein (e.g. Ghijsen et al., 1999; Ueda et al., 2001; Crino 
et al., 2002;Gorter et al., 2002) in animal epileptic models. Some have on the other hand 
found an increase in EAAT1 mRNA (Nonaka et al., 1998) and decreased EAAT3 mRNA 
(Akbar et al., 1998), while Simantov et al. found a down-regulation of EAAT3 and a 
modest increase in expression of EAAT2 in restricted hippocampal regions (Simantov et 
al., 1999). 
There are a few studies reporting on glutamate transporters in human epileptic 
patients. Tessler and colleagues (Tessler et al., 1999) found no change in the level of the 
mRNA or protein, by using in situ hybridization and Western blotting techniques 
respectively, for EAAT1 and EAAT2 in hippocampus and temporal cortex in temporal 
lobe epilepsy (TLE) patients compared to post mortem controls. In a study by Mathern 
and colleagues using immunocytochemical methods coupled with neuronal counting and 
image analysis, no changes in EAAT1 immunoreactivity (IR) were observed in 
hippocampi from TLE patients with hippocampal sclerosis compared with TLE patients 
without hippocampal sclerosis. Decreased EAAT2-IR was, in the same study, associated 
with neuronal loss. An increased EAAT3-IR was seen in areas where neurons were 
spared and a decrease in areas with neuronal loss (Mathern et al., 1999). A recent study 
from Proper et al. showed a general decrease in EAAT1-IR and EAAT2-IR in the 
sclerotic hippocampus when compared with the non-sclerotic hippocampus or post 
mortem controls (Proper et al., 2002). This decrease was accompanied by a decrease in 
mRNA levels for both transporters. An increase in neuronal EAAT3 protein levels in the 
resistant areas (CA2, granule cell layer and subiculum) in the hippocampal sclerosis 
group was also observed. Using immunohistochemistry and quantitative western blots 
Eid et al. found no difference in EAAT2 expression between non-MTLE and MTLE 
hippocampi (Eid et al., 2004). 
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Materials and Methods 
Patient Tissue  
Patients with medically intractable temporal lobe epilepsy underwent phased 
presurgical evaluation at the Yale-New Haven Hospital, and appropriate candidates 
underwent anteromedial temporal lobectomy with hippocampectomy according to 
standard procedures (Spencer, 1984). Informed consent from each patient and 
institutional approval were obtained for the use of tissue in this project. The surgically 
resected hippocampi were classified into two groups: (1) mesial temporal lobe epilepsy 
(MTLE) and (2) non-MTLE as described by Eid et al. (Eid et al., 2004). The MTLE 
hippocampus was characterized by pronounced neuronal loss (>50%) and extensive 
astroglial proliferation most pronounced in the hippocampal subfields CA1, CA3, and 
hilus (Kim, 2001). Reorganization of peptidergic neurons (neurons containing dynorphin, 
somatostatin, neuropeptide Y, and substance P) in the dentate gyrus was also seen (de 
Lanerolle et al., 1994). On the other hand the non-MTLE hippocampi were recognized by 
a modest (<25%) neuronal loss throughout all hippocampal subfields, minimal astroglial 
proliferation, and no reorganization of peptidergic neurons in the dentate gyrus (Kim, 
2001). They were obtained from patients with a mass lesion in the temporal lobe outside 
the hippocampus (MaTLE) and those with no clear etiology, described previously as 
paradoxical temporal lobe epilepsy –PTLE (de Lanerolle et al., 1997). 
Tissue preparation  
Immediately after surgical resection two 5 mm thick slices were cut from the mid-
portion of the hippocampus. One of the samples was immersed into a fixative containing 
4 % formaldehyde and 15 % (v/v) of a saturated picric acid solution in 0.1 M phosphate 
buffer pH 7.4 (PB) for 1 hour, followed by immersion into 5 % acrolein in PB for 3 
hours. Thereafter the tissue was rinsed and stored in PB at 4 °C. Fifty-micrometer coronal 
sections were cut on a Vibratome and processed for immunohistochemistry. The other 
sample was rapidly frozen on dry ice, stored at –80 °C, and later used for Western blots. 
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Hippocampal Nomenclature  
The mesial temporal lobe consists of the hippocampus, parahippocampal gyrus, 
entorhinal cortex and amygdala. The hippocampus is commonly divided into the 
subiculum, Ammon’s horn and dentate gyrus (Lorente de Nó, 1934). The Ammon’s horn 
is further subdivided into the areas CA1, CA2 and CA3, while the dentate gyrus is 
subdivided into the hilus, granule cell layer and molecular layer (Amaral and Insauti, 
1990). 
Antisera and chemicals  
Antibodies against GLAST and GLT were prepared by immunizing rabbits with 
synthetic peptides (A522-541 (PYQLIAQDNEPEKPVADSET) for GLAST and B563-
573 (SVEEEPWKREK) for GLT) coupled to keyhole limpet hemocyanin with 
glutaraldehyde (Lehre et al., 1995; Danbolt et al., 1998). The corresponding anti-peptide 
antibodies were referred to as anti-A522 (rabbit 8D0161; Ab, 314) and anti-B563 (rabbit 
1B0707; Ab, 355). These antibodies were tested and characterized by Western blotting 
(Fig. 1) and immunohistochemical methods, and cross-reacted with human GLAST and 
GLT, respectively. Unless otherwise specified, all other chemicals were obtained from 
Sigma-Aldrich (St. Louis, MO).  
Immunohistochemistry and electron microscopy  
Vibratome sections were incubated free-floating in anti-A522 (200 ng/ml) or anti-
B563 (200 ng / ml) antibodies for 24 hours (RT), and then processed according to the 
avidin-biotin peroxidase method (Hsu et al., 1981) using a commercially available kit 
(Vectastain Elite, Vector Laboratories, Burlingame, CA). Immunstained sections from 
each patient were mounted on slides, dehydrated and coverslipped for light microscopic 
analysis. Control sections incubated without the primary antibody or by replacing it with 
preimmune sera were not immunostained. Additional immunostained sections were 
processed for electron microscopy. After immunostaining as described above the sections 
were treated with 2 % osmium tetroxide in PB, stained en bloc with 2 % uranyl acetate in 
water, dehydrated and flat-embedded in Durcupan ACM. Sections were cut on an 
ultramicrotome, transferred to 500-mesh copper grids (Electron Microscopic Sciences, 
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Fort Washington, PA, USA), contrast-stained with lead citrate and examined in a 
transmission electron microscope (Jeol 1200 EX II) at 60 kV.  
Western blot Analysis  
Sections containing all hippocampal subregions were cut from frozen non-MTLE 
and MTLE specimens. The tissue was homogenized in 10 tissue volumes of SDS-
solubilization buffer (1 % SDS with 150 mM NaCl and 10 mM PB pH 7.4, 5mM EDTA, 
and 1 mM PMSF) using a FastPrep® Instrument (Qbiogene, Inc., Ca) and the FastRNA® 
Pro Green Kit (Qbiogene, Inc., Ca). The homogenates were then incubated for 10 min 
and centrifuged (1000 x g, 10 min, 15°C). The supernatant solutions were stored at 80°C.  
The sample protein concentrations were determined using BCA Protein Assay Kit 
(Pierce, #23227) and the determination was preformed according to manufacturer’s 
protocol. Bovine serum albumin (BSA) was used as standard and the spectrophotometer 
(GeneQuant pro, Amersham) was set to 562 nm. The extracts were then subjected to 
SDS-PAGE (Laemmli, 1970) and electroblotted (Towbin et al., 1979) to nitrocellulose 
(100v, 1h). The Protein homogenates were diluted to a final protein concentration of 2 
mg/ml in a loading buffer (10 % sucrose, 2 % (w/v) SDS (pure C12; Pierce 28312), 0.001 
% (w/v) bromophenol blue, 62.5 mM Tris-HCl pH 6.8, and 5% 2-mercaptoethanol) and 
applied at different concentration on precast polyacrylamide gels (Criterion, 10% Tris-
HCl, BIORAD). The gels were run (200V, 40 min) in CriterionTM Cell Electrophoresis 
Module (BIORAD). Immunostaining of blots was done as previously described (Lehre et 
al., 1995) at room temperature. The immunolabeling of the blots was preformed using 
Supersignal West Dura Extended Duration Substrate (Pierce, cat#34075). First the 
nitrocellulose blots were washed (1x1min) in TBST (150mM NaCl, 0.05% (v/v) Tween 
20, 0.05% (w/v) sodium azide and 10mM Tris-HCl pH 8), blocked (30 min) in TBST 
with 4 % (w/v) skimmed milk powder (Nestle, Carnation, instant nonfat dry milk), 
washed (1 x 1 min) with TBST and incubated (overnight) with primary antibodies (200 
ng / ml anti-A522 or 200 ng / ml anti-B563) in TBST with 1% BSA (Sigma A-7888) and 
0.05% (w/v) sodium azide. The blots were washed (1x1 min and 3x5-10 min) in TBST 
without azide, incubated 1 hour with peroxidase conjugated (HRP-Conjugated) anti-
rabbit IgG (Anti-rabbit IgG peroxidase conjugate, A-1949, Sigma, diluted 1:30000) in 
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TBST with 4 % dry milk (without azide) on a shaker. The blots were incubated for 5 min 
in Supersignal Substrate according to manufacturers protocol (Pierce, Prod # 34075), 
after they had been washed (1x1 min and 3x5-10 min) with TBST (without azide). The 
blots were read at a Kodak Image 2000 R and the intensity of the bands was calculated 
for GLAST and GLT using the Kodak software. A standard curve was made with 
increasing concentrations of homogenized hippocampal tissue from a non-MTLE patient 
to determine the linear range and 3, 6, and 12 µg protein were used from each patient. 
Both antibodies gave a strong single band consistent with the expected molecular mass of 
the glial glutamate transporters. Substitution of the primary antibodies with normal serum 
completely abolished the staining. The blots were assessed using a two-tailed Mann-
Whitney U test (Statview Software, SAS Institute, NC).  
Results  
Clinical characteristics of patients  
The demographic and clinical characteristics of the patients used in this study 
were similar to those in a larger sample reported previously (de Lanerolle et al., 2003) 
(Table 1). Similar numbers of males and females were studied in the non-MTLE group, 
but the male:female relationship was 5:8 in the MTLE group. Eight of the 10 non-MTLE 
hippocampi were of the PTLE category (Table 1). The ages at surgery of the patients in 
the MTLE group were not significantly different (MTLE mean 37 years ± 4 SEM and 
non-MTLE 26 years ± 5 SEM, p = 0.082, Mann-Whitney U, two-tailed test). The 
duration of seizure history prior to surgery was also not significantly different (MTLE 27 
±2 and non-MTLE 19 ±4 years, p = 0.0585, Mann-Whitney U, two-tailed test). All 
MTLE patients had hippocampal sclerosis characterized by significant neuronal loss 
easily seen in area CA1 (neuronal counts not shown) compared to non-MTLE. There was 
no difference between groups as regards the antiepileptic drugs they were on at the time 
of surgery.  
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Table 1 – Patient Characteristics 
Patient and 
classification 
Gender Age at 
Surgery 
(years) 
 
Years since 
first seizure 
to surgery 
Antiepileptic drugs at 
surgery 
 
Pathology 
 
Non-MTLE      
1 M 24 24 GBP, PHT, TPM PTLE 
2 F 34 21 CBZ PTLE 
3 F 5 5 PHT Ischemic stroke 
4 F 15 15 LEV, OXC Cortical dysplasia 
5 F 50 42 LEV PTLE 
6 M 5 4 CLP, ZNS, TPM,  PTLE 
7 M 34 21 CBZ PTLE 
8 F 43 34 CBZX, LTG, TPM PTLE 
9 M 10 10 LTG, PHT PTLE 
10 M 44 18 CBZX, CZP PTLE 
      
MTLE      
11 M 37 31 CBZ Hippocampal Sclerosis 
12 F 40 38 GBP, LTG, LEV Hippocampal Sclerosis 
13 F 18 17 CBZX Hippocampal Sclerosis 
14 F 39 36 CBZ, PRM Hippocampal Sclerosis 
15 F 25 25 CBZX Hippocampal Sclerosis 
16 F 52 27 PHT, VPA Hippocampal Sclerosis 
17 F 51 40 CBZ Hippocampal Sclerosis 
18 F 52 33 CBZX Hippocampal Sclerosis 
19 M 47 10 LTG, LEV, CBZX Hippocampal Sclerosis 
20 M 17 17 CBZ, PHT Hippocampal Sclerosis 
21 M 53 50 CBZ, PRM Hippocampal Sclerosis 
22 M 28 26 CBZ, PHT Hippocampal Sclerosis 
23 F 26 26 CBZ Hippocampal Sclerosis 
 
Table 1: Characteristics of patients selected for the study. Abbreviations for anti-epileptic drugs: 
Carbamazepine/Tegretol (CBZ), Gabapentin/Neurontin (GBP), Phenytoin/Dilantin (PHT), 
Topiramate/Topamax (TPM), Lamotrigine/Lamictal (LTG), Levetiracetam/Keppra (LEV), 
CarbamzepineXR (CBZX), Primidone/Mysoline (PRM), Valproic Acid/Depakote (VPA), 
Clorazepate/Tranxene (CLP), Oxcarbazepine/Trileptal (OXC) 
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Figure 1 
(A) Immunoblots of crude SDS extracts of human neocortex which were subjected to SDS-PAGE (~ 50 µg 
protein/lane) and reacted with EAAT1 (GLAST) (anti A522, 200 ng/ml, lane 1) and EAAT2 (GLT) (anti-
B563, 200 ng/ml, lane 2) antibodies followed by alkaline phosphatase conjugated secondary antibodies. 
Both antibodies gave a band at the expected molecular weight for each of the glutamate transporters. 
Substitution of normal serum for the primary antibodies abolished staining (lane 3). Molecular mass 
markers (kDa) are shown alongside the blots. (B) A bar plot showing the relative amounts of EAAT1 
(GLAST) and EAAT2 (GLT) (expressed as a percentage of the non-MTLE mean) quantified from Western 
blots for non-MTLE (n=6) and MTLE (n=9) hippocampi. No significant differences in GLAST (EAAT1) 
or GLT (EAAT2) were detected between patient groups. 
Western blotting  
Western blot studies of the transporters GLAST and GLT were carried out on 
whole hippocampal sections from non-MTLE and MTLE hippocampi to determine if 
there was an overall difference in the levels of these transporters between patient groups 
(figure 1). No statistically significant difference in the expression of GLAST and GLT 
between the non-MTLE and MTLE hippocampi was observed (GLAST: p = 0.27, GLT: 
p = 0.95, Mann-Whitney U, two-tailed test). However, since such a result may also be 
produced in the face of regional changes in distribution, which may be compensatory, an 
immunohistochemical study of the distribution of GLAST and GLT was undertaken. 
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Cellular localization of GLAST and GLT 
 In both non-MTLE and MTLE hippocampi both EAAT1 and EAAT2 were 
localized to astrocytes, being seen in both somata and processes of these cells (Fig. 2D, 
2E, 3D, 3E). The staining was around neurons sometimes outlining them (Fig. 2C-F, 3C-
F). No neuronal labeling was detected.  
 At the ultrastructural level localization of EAAT1 and EAAT2 the 
immunoreactivity was studied in area CA1 of the hippocampus in both MTLE and non-
MTLE patients (Fig. 4). CA1 was chosen as sclerosis is most prominent in this area of the 
hippocampus. Only astrocytes were labeled, processes (Fig.4A) as well as somata. 
Labeled astrocytic processes could be seen to separate unlabeled pyramidal cell bodies 
and terminals (Fig. 4B, C, D). The immunostained somata contained the organelles 
typical for astrocytes. Though they were adjacent to strongly labeled astrocytic processes, 
the axon terminals themselves always appeared completely unlabeled (Fig. 4B, 4D). The 
labeling was entirely intracellular. In moderately reacted preparations the 
diaminobenzidine reaction product appeared concentrated close to the inner surface of the 
plasma membrane sparing the outer lamina (Fig 4E). The extracellular space always was 
free of reaction product. Fibrous astrocytes in white matter were also labeled (Fig. 4F). 
Strong immunolabeling for EAAT1 and EAAT2 was also seen at the endothelial-
astrocyte interface with the labeling on the astrocyte membrane (Fig. 4E). Such labeling 
was seen in both non-MTLE and MTLE tissue. 
Regional distribution of immunolabeling 
 The pattern of immunolabeling for EAAT1 and EAAT2 in non-MTLE differed 
somewhat from the MTLE group. Overall, there was weaker EAAT1 than EAAT2 
immunostaining. EAAT1 and EAAT2 were expressed in all subfields of both non-MTLE 
and MTLE hippocampi. The immunoreactivity was homogeneous and seen in all 
sublayers, but a patchy pattern, was seen in some subareas such as CA1 for both EAAT1 
and EAAT2 in non-MTLE and MTLE (Fig. 2A, 2B, 3A, 3B), as earlier described for 
GLT in post mortem material (Milton et al., 1997; Proper et al., 2002). 
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Dentate gyrus and hilus  
 The staining of both GLAST and GLT was mainly around pyramidal cells in hilus 
(not shown) and granule cells (figure 2c-d and 3c-d), outlining the neurons, and 
individual labeled astrocyte cell bodies were seen in the dentate molecular layer and 
polymorphic layer (not shown) in both non-MTLE (Fig. 2C, 3C) and MTLE (Fig. 2D, 
3D). In MTLE compared to non-MTLE a loss of GLAST immunoreactivity was visually 
observed throughout these two regions (Fig. 2B). The immunoreactivity for GLT in the 
molecular layer of MTLE hippocampi, was less uniform than in the non-MTLE, with 
some regions of the molecular layer showing even stronger labeling (Fig. 3B).  
Some areas of the hilus in MTLE also retained EAAT1 and EAAT2 immunoreactivity 
and individual labeled astrocytes were seen in these resistant areas (not shown). Blood 
vessels were outlined by the immunostaining for both EAAT1 and EAAT2 in all 
hippocampi (Fig 2C, 2D, 3C, and 3D).  
Hippocampal area CA1  
 The CA1 region in the MTLE is clearly sclerotic and smaller in size then the non-
MTLE hippocampus (Fig 2B, 3B). The staining of both EAAT1 and EAAT2 were mainly 
around pyramidal cells in non-MTLE (Fig 2E, 3E). The neurons were outlined, but not as 
clearly as around the granule cells. It was hard to distinguish individual astrocytes due to 
an intricate meshwork of labeling in stratum radiatum, stratum pyramidale, and stratum 
oriens in non-MTLE hippocampi (not shown). In the MTLE hippocampi, the intensity of 
immunoreactivity for both GLAST and GLT appeared reduced in astrocyte cell bodies 
compared the non-MTLE area CA1, and this was associated with the neuronal loss and 
astroglial proliferation in CA1 (Fig. 2F, 3F).  
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Figure 2 
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Hippocampal area CA3, CA2 and subiculum  
 The immunostaining for both GLAST and GLT in these regions was also mainly 
in fine processes around pyramidal neurons, but individual astrocytes were seen in 
stratum radiatum, stratum oriens, and subiculum in both non-MTLE and MTLE (not 
shown). Blood vessels were outlined by the staining for both GLAST and GLT in both 
groups of hippocampi, specially pronounced in subiculum. In the MTLE hippocampi, 
weaker immunoreactivity for GLAST was apparent in CA3 and CA2, whereas for GLT 
no noticeable differences were observed. The subiculum did not show any loss of 
immunoreactivity for either transporter in either group of hippocampi (Fig. 2B, 3B). 
Individual astrocytes cell bodies labeled for GLAST and GLT were observed in MTLE. 
(not shown).  
White matter and alveus 
A few astrocytes labeled with GLAST and GLT were seen in alveus and the white matter 
in both non-MTLE and MTLE groups (not shown).  
 
Figure 2 (page 16) 
Photomicrographs of EAAT1 (GLAST)-like immunoreactivity in non-MTLE (PTLE) and MTLE 
hippocampi. (A) and (B) are low power views of the entire cross-section of a non-MTLE and MTLE 
hippocampus respectively. At this magnification the immunoreactivity appears as darkened areas in these 
figures.  In the non-MTLE (A) the immunoreactivity is seen in the dentate ML, throughout the Ammon’s 
horn (CA3, CA2, CA1) and subiculum. In Ammon’s horn and the subiculum immunoreactivity appears 
patchy as previously reported (Milton et al. 1997). In the MTLE (B) the immunoreactivity appears weaker 
except in the subiculum. (C) and (D) are higher magnifications of the dentate gyrus showing parts the 
granule cell layer (GCL), polymorphic layer (PML) and molecular layer (ML) in non-MTLE and MTLE 
respectively showing fine immureactive processes around the granule cells (asterisks) and blood vessels 
(arrow heads) as  well as astrocytic cell bodies (arrows). (E) and (F) are portions of area CA1 in non-MTLE 
and MTLE hippocampi showing immunoreacitve astrocytes (arrows) and processes, some of which 
surround blood vessels (arrow heads) (E), which are more diffusely stained in MTLE hippocampi (F). Bar 
= 100 µm in A and B, and 20 µm in C-F. 
 
Figure 3 (page 18) 
Photomicrographs of EAAT2 (GLT)-like immunoreactivity in non-MTLE (PTLE) and MTLE hippocampi. 
(A) and (B) are low power views of the entire cross-section of a non-MTLE and MTLE hippocampus 
respectively. At this magnification the immunoreactivity appears as darkened areas in these figures.  In the 
non-MTLE (A) the immunoreactivity is seen more prominently in the dentate ML, and throughout the 
Ammon’s horn (CA3, CA2, CA1) and subiculum. In the MTLE (B) the immunoreactivity appears weaker 
in the hilus, CA3, CA2 and CA1 but more intense in the subiculum. (C) and (D) are higher magnifications 
of the dentate gyrus showing parts the granule cell layer (GCL), polymorphic layer (PML) and molecular 
layer (ML) in non-MTLE and MTLE respectively, In both types of hippocampi fine immunoreactive 
processes surround the granule cells (asterisks) and blood vessels (arrow heads). Labeled astrocytic cell 
bodies (arrows) are also seen. (E) and (F) are portions of area CA1 showing immunoreacitve astrocytes 
(arrows) and processes which strongly surround blood vessels (arrow heads (E). The immunostaining is 
more diffuse in MTLE hippocampi (F). Bar = 100 µm in A and B, and 20 µm in C-F. 
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Figure 3  
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Discussion 
In this study we demonstrate both at the light microscopic and ultrastructural level 
that in the human hippocampus both EAAT1 and EAAT2 are found in astrocytes. No 
immunoreativity for these two proteins was observed in neurons. This finding is fully 
consistent with the localization of EAAT1 and EAAT2 in the rat hippocampus (Lehre et 
al., 1995). In contrast, one study of the human hippocampus has reported EAAT2 mRNA 
in neurons as well. This has not been corroborated in the immunohistochemical studies 
by these same workers or by in situ hybridization or immunohistochemistry in any other 
studies (Lehre et al., 1995; Mathern et al., 1999; Tessler et al., 1999). 
Prior studies of the distribution of EAAT1 and EAAT2 in surgically removed 
human sclerotic hippocampi compared to non-sclerotic hippocampi have concluded that 
there is a reduction in EAAT2 (Proper et al., 2002; Mathern et al., 1999), a slight or no 
reduction in EAAT1 (Proper et al., 2002; Mathern et al., 1999) or essentially no-change 
in these transporters (Tessler et al., 1999). The Western blot data presented in the current 
study suggests that there is no change in the levels of either EAAT1 or EAAT2, though 
immunohistochemical localization shows weaker staining in sclerotic regions like CA1 
and the hilus compared to that in non-sclerotic hippocampi. This apparent discrepancy 
needs explanation. 
Careful perusal of previous reports of reduced astrocyte glutamate transporters in 
the sclerotic hippocampus from patients with TLE, show that the actual evidence for such 
reduction is not compelling. Firstly the two studies that report a reduction of glutamate 
transporters, especially of EAAT2, do so on the basis of immunohistochemistry on fixed 
tissue (4% formaldehyde for 24 - 48 hr), whereas those that assessed transporter levels in 
parallel with immunoblots report no change (Tessler et al., 1999 and this study). It is well 
known that fixatives reduce the antigenicity of molecules and do not provide a reliable 
basis for quantification (Danbolt, 2001).  
Evaluation of immunohistochemical data also presents further issues for discussion. The 
data presented in Proper et al (Proper et al., 2002) show that staining levels for EAAT1 
quantified as a Relative Optical Density (ROD) measure show a reduction only for the 
dentate polymorphic layer (PML) in the sclerotic compared to the non-sclerotic 
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hippocampus, despite the demonstration in their immunohistochemical photomicrographs 
of reductions in staining in area CA1 and CA3/CA2 (see Fig. 2 Proper et al., 2002). 
Mathern et al (Mathern et al., 1999) also find no difference in EAAT1 immunostaining 
levels between sclerotic and non-sclerotic hippocampi. Thus in essence all previous 
studies concur with our data that there is no difference in EAAT1 levels. Comparisons 
that report reductions relative to autopsy controls must be interpreted with caution as 
postmortem changes are in general likely to results in changes of glutamate transporter 
levels due to autolytic effects (Beckstrøm et al., 1999).  
EAAT2 is the predominant glutamate transporter in the hippocampus (Danbolt et 
al., 1992; Haugeto et al., 1996; Tanaka et al., 1997; For review and discussion see 
Danbolt, 2001). Proper et al (Proper et al., 2002) report on the basis of 
immunohistochemical staining that EAAT2 levels in areas CA1, CA2, CA3 and CA4 
were reduced. Unlike for EAAT1, the immunohistochemical patterns and well as their 
ROD quantification are generally in concordance for EAAT2. However, in situ 
hybridization studies by the same group show no quantitative change in EAAT2 in areas 
CA1 and CA2 (Fig 6B Proper et al., 2002) between sclerotic and non-sclerotic 
hippocampi. Even though the granule cell layer in the sclerotic hippocampus appears 
visually to have a considerable reduction in mRNA (see Fig. 5F and 5G Proper et al., 
2002) no quantitative difference is recorded (Fig. 6B Proper et al., 2002). Thus the data 
for EAAT2 as presented in this study is equivocal at best. In a study using similar 
surgical tissue and patient types and fixed similar to that of the study by Proper et al., 
Mathern and co-workers found a reduction in EAAT2 only in the hilar area of sclerotic 
hippocampi (see Fig. 11 Mathern et al., 1999).  
No depletion of EAAT2 is shown for CA1 either in gray value measures or 
immunoreactivity pattern shown in the illustrated figures (Fig 6E and F Mathern et al., 
1999). Tessler et al (1999) also found no difference in EAAT2 levels between epileptic 
hippocampi and postmortem controls; this study did not distinguish between sclerotic and 
non-sclerotic hippocampi (Tessler et al., 1999). On the basis of these studies it would be 
reasonable to conclude that there is no appreciable difference in EAAT2 levels as well 
between sclerotic and non-sclerotic hippocampi. 
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Figure 4 
Electron micrographs of GLAST and GLT immunoreactivity in CA1 of hippocampus in non-MTLE and 
MTLE patients demonstrating labeling of astrocytic processes (a). Similar staining pattern was found for 
both antibodies in non-MTLE and MTLE. A, B, D, and E are from CA1 of a representative non-MTLE 
hippocampus, while C and F are from MTLE. Both A and C show a large stained astrocytic cell process, 
while B and D show small processes adjacent to axospinous synapses. Note that the staining appears 
concentrated close to the inside of glial membranes (arrowheads) and that axospinous synapses (s, t) are 
always unlabeled. Electron microscopy of the endothelial-astrocyte interface in CA1 of a representative 
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non-MTLE hippocampus (E) demonstrates strong labeling on the astrocyte membrane facing the 
endothelial cell. Labeling with GLAST and GLT gave the same perivascular astrocytic staining pattern in 
both non-MTLE and MTLE hippocampi. F shows GLAST labeling in fibrous astrocyte (gf) in alveus of 
CA1. Abbreviations: a, astrocytic cell process; ax, myelinated axon; bm, basal lamina; e, endothelial cell; 
ery, erythrocyte; gf, fibrils in astroglial process; m, mitochondrium; t, axon terminal; s, dendritic spine; L, 
capillary lumen;. Antibodies: Anti-A522 1 µg/ml (A, B, and G) and anti-B563 3 µg/ml (D and E). Scale 
bars: A, 800 nm, C, D, and F, 500 nm, B and D, 200 nm.  
 
However, in the immunohistochemical localization studies shown in this paper as 
well as others, why does there appear to be reduced immunoreactivity in areas such as 
CA1 and the hilus in sclerotic hippocampi, while immunoblot analyses show no 
difference?  There are some possible explanations for this. The first may be that in areas 
such as CA1 where there is an apparent reduction in staining intensity, this may only be 
reflective of a redistribution of the transporter throughout the astrocytic processes in the 
sclerotic hippocampi rather than a true reduction in level. Evidence in support of this is 
that ultrastructural localization studies show EAAT2 immunoreactivity throughout 
astrocytic process despite apparent loss suggestive in light microscopy (present study). 
Likewise confocal immunohistochmical studies reveal EAAT2 immunoreactivity 
throughout astrocyte processes, even though staining in somata is reduced (Eid et al., 
2004). Such redistribution of EAAT2 transporter in epileptic surgical tissue has 
previously been suggested by others (Tessler et al., 1999). An alternative possibility is 
that there may be compensatory changes in the expression of transporters in its different 
regions. Such a possibility is recognized in suggestive upregulation of transporter in 
subiculum and molecular layer (our study) with the apparent down regulation in other 
areas. 
Previous studies of the distribution of glutamate transporters (Proper et al., 2002; 
Mathern et al., 1999) have postulated a reduction in glutamate transporters to explain the 
striking physiological observation that there are elevated levels of extracellular glutamate 
in the epileptogenic (sclerotic) hippocampus (During and Spencer, 1993; Cavus et al., 
2005) during seizures. Our own findings, like those of Tessler et al. (Tessler et al., 1999) 
find little support for a role of glutamate transporters in this phenomenon.  
On the contrary, there are several plausible alternative explanations for such 
elevated extracellular glutamate levels. One possibility may be related to the down 
regulation of glutamine synthetase in astrocytes in sclerotic areas of the hippocampus, 
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which has been argued as a possible cause (Eid et al., 2004). Alternatively, or in addition, 
increased levels of inflammatory factors such as interleukin 1β and chemokines in 
sclerotic hippocampi are now recognized as able to cause the release of glutamate from 
astrocytes, which may be the source of the increased glutamate (data reviewed in de 
Lanerolle and Lee, 2005). These mechanisms may be more pertinent to elevated 
extracellular glutamate in sclerotic seizure foci than alterations in transporter levels or 
their function and certainly merit further study. 
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Results other papers 
Results Abstract 1 
Rats were stressed by immobilization for 7 hours and the transporter 
immunoreactivities were then determined in hippocampus, hupotahlamus and frontal 
cortex by quantitative immunoblotting 3, 7, 15, and 24 hours after termination of 
immobilization stress. We found the GAT1 immunoreactivity was significantly increased 
in hippocampus by a maximum of 57 ± 18 % (mean ± SEM) after 3 hours. This effect 
was still detectable after 24 hours. There were no significantly effects on the 
immunoreactivities of the other transporters, with a possible exception of GAT3 in the 
hypothalamus. Injection (i.p) of corticosterone-21-acetate (10 mg / kg) did not result in a 
similar up-regulation of GAT1. In conclusion, our data show that immobilization stress 
up-regulates GAT1 in the hippocampus, but we now think that newer methods (ECL) and 
accurate measurements (pipetting robot) might show changes in other transporters. We 
are planning to repeat this experiment.  
 
Results Paper 2 
Animals were immunized with synthetic peptides corresponding to different parts 
of the EAAT3-sequence. Because the antibodies were affinity purified, all antibodies 
used in this paper recognized the peptides used to generate them. In order to produce 
good anti-peptide antibodies, we show that the key factor is to select the right parts of the 
sequence for peptide synthesis.  
The anti-C479, anti-C491, and the anti-C510 antibodies labeled the same broad 
fuzzy band around 70 kDa on immunoblotting, while other antibodies generated by 
immunization and purification (C1-13, C1-18, C39-58, C81-94 and C468-482) did not 
recognize EAAT3. In addition to the 70 kDa band the anti-C479 antibodies labeled a 
broad band just below the 66 kDa marker. The identity of the lower anti-C479 positive 
band was uncovered by testing the antibodies for reactivity toward proteins present in 
high concentrations in axons. A strong and specific reaction to tubulin was observed, but 
no to any of the other proteins tested, including another abundant cytoskeletal protein, 
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actin. This result indicated that the anti-C479 antibodies recognized both tubulin and 
EAAT3 despite of being affinity purified against the corresponding peptide. The 
antibodies to EAAT3 and to tubulin were separated by absorption of crude serum from 
the original immunized rabbit on columns containing glutaraldehyde-treated bovine 
serum protein, KLH (carrier protein to which the peptide was conjugate during 
immunization), tubulin, and the C479-498 peptide. The antibodies that were eluted from 
the last column with the C479-498 peptide did not recognize the lover band labeled by 
the non-absorbed anti-C497 antibodies. Absorption against tubulin removed the 
antibodies labeling labeling the lower band.  
To verify that the band expected to represent EAAT3 really did so, the antibodies 
were tested by immunoblotting with protein extracts from wild-type and EAAT3 knock-
out mice. The band detected in the wild type were exactly as would be observed in rat 
tissue, while neither the absorbed anti-C479 nor anti-C491 antibodies showed any bands 
on the blots from the EAAT3 knock-out mice.  
The results illustrate that immunization with an antigen may lead to the generation 
or antibodies that recognize not only the antigen, but also molecules that appear 
completely unrelated to the antigen. The conclusions are that not all antibodies to 
synthetic peptides recognize the native protein and that the specificity of an antibody is 
hard to predict. Unwanted reactivity can be highly specific and thereby hard to recognize. 
In this case, cross-reactivity was discovered because antibodies to different epitopes gave 
different epitopes gave different labeling patterns.  
 
Results Paper 3 
Hippocampi removed from patients with mesial temporal lobe epilepsy show 
evidence of impaired water and K+ homeostasis. According to experimental studies, the 
processes responsible for clearance of extracelluar K+ are compromised by removing 
perivascular AP4. This suggests that an efficient clearance of K+ depends on a 
concomitant water flux through astrocyte membranes. Therefore, we hypothesized that 
loss of perivascular AQP4 might be involved in the pathogenesis of MTLE. Whereas 
Western blot analysis showed an overall increase in AQP4 levels in MTLE compared 
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with non-MTLE hippocampi, quantitative ImmunoGold electron microscopy revealed 
that the density of AQP4 along the perivascular membrane domain of astrocytes was 
reduced by 44% in area CA1 of MTLE vs. non-MTLE hippocampi. There was no 
difference in the density of AQP4 on the astrocyte membrane facing the neuropil. 
Because anchoring of AQP4 to the perivascular astrocyte endfoot membrane depends on 
the dystrophin complex, the localization of the 71 kDa brain-specific isoform of 
dystrophin was assessed by immunohistochemistry. In non-MTLE hippocampus, 
dystrophin was preferentially localized near blood vessels. However, in the MTLE 
hippocampus, the perivascular dystrophin was absent in sclerotic areas, suggesting that 
the loss of perivascular AQP4 is secondary to a disruption of the dystrophin complex.  
Based on the present findings, we conclude that mislocalization of AQP4 might 
contribute to the epileptogenicity of the MTLE hippocampi. This conclusion does not 
necessarily mean that the changes observed are primary events in the pathogenesis of 
MTLE. It could well be that the mislocalization develops late in the sequence of events 
that culminates in epilepsy. Irrespective of the temporal course of events, our findings 
have identified a molecular mechanism that could be targeted pharmacologically to 
reduce brain excitability.  
 
 - 66 - 
References 
 
Akbar, M.T., Rattray, M., Williams, R.J., Chong, N.W.S., and Meldrum, B.S., 1998. 
Reduction of GABA and glutamate transporter messenger RNAs in the severe-seizure 
genetically epilepsy-prone rat, Neuroscience, 85, pp. 1235-1251. 
 
Amaral, D. G. and Insauti, R., 1990. Hippocampal Formation, In: The Human Nervous 
System, Ed: G. Paxinos, Academic Press, New York, pp. 711-756. 
 
Arriza, J.L., Eliasof, S., Kavanaugh, M.P., and Amara, S.G., 1997. Excitatory amino acid 
transporter 5, a retinal glutamate transporter coupled to a chloride conductance, 
Proceedings of the National Academy of Sciences of the United States of America, 94, 
pp. 4155-4160. 
 
Barbour, B., Brew, H., and Attwell, D., 1988. Electrogenic glutamate uptake in glial cells 
is activated by intracellular potassium, Nature, Sep 29, 335(6189), pp. 433-435. 
 
Beckstrøm, H., Julsrud, L., Haugeto, Ø., Dewar, D., Graham, D.I., Lehre, K.P., Storm-
Mathisen, J., and Danbolt, N.C., 1999. Interindividual differences in the levels of the 
glutamate transporters GLAST and GLT, but no clear correlation with Alzheimer's 
disease, Journal of Neuroscience Research, 55, pp. 218-229. 
 
Berger, U.V., Hediger, M.A., 1998. Comparative analysis of glutamate transporter 
expression in rat brain using differential double in situ hybridization, Anatomy and 
Embryology (Berl), 198, pp. 13-30. 
 
Bergles, D.E., Roberts, J.D., Somogyi, P., and Jahr, C.E., 2000. Glutamatergic synapses 
on oligodendrocyte precursor cells in the hippocampus, Journal of Neurochemistry,405, 
(6783), pp. 187-191. 
 
 - 67 - 
Billups, B., Rossi, D., and Attwell, D. 1996. Anion conductance behavior of the 
glutamate uptake carrier in salamander retinal glial cells. Journal of Neuroscience, Nov 1, 
16(21), pp. 6722-6731. 
 
Broman, J., Hassel, B., Rinvik, E., Ottersen, O.P., 2000. Biochemistry and anatomy of 
transmitter glutamate. In: Ottersen, O.P., Storm-Mathisen, J., eds. Glutamate, Elsevier 
Science, Amsterdam, pp. 1-44. 
 
Brooks-Kayal, A.R., Munir, M., Jin, H., Robinson, M.B., 1998. The glutamate 
transporter, GLT-1, is expressed in cultured hippocampal neurons. Neurochemistry 
International, 33, pp. 95-100. 
 
Cavus, I., Kasoff, W.S., Cassaday, M.P., Jacob, R., Gueorguieva, R., Sherwin, R.S., 
Krystal, J.H., Spencer, D.D., and Abi-Saab, W.M., 2005. Extracellular metabolites in the 
cortex and hippocampus of epileptic patients, Annals of neurology, 57, pp. 226-35. 
 
Chadwick, D., 1990. The epidemiology of drug resistant epilepsy and adverse effects of 
antiepileptic drugs, Acta Neurochirurgica Supplement (Wien), 50, pp. 32-37. 
 
Chaudhry, F.A., Lehre, K.P., van Lookeren Campagne, M., Ottersen, O.P., Danbolt, 
N.C., and Storm-Mathisen, J., 1995. Glutamate transporters in glial plasma membranes: 
highly differentiated localizations revealed by quantitative ultrastructural 
immunocytochemistry, Neuron, 15, pp. 711-720. 
 
Cohen, I., Navarro, V., Clemenceau, S., Baulac, M. and Miles, R., 2002. On the origin of 
interictal activity in human temporal lobe epilepsy in vitro, Science, 298, pp. 1418–1421.  
 
Collingridge, G.L. and Lester, R.A., 1989. Excitatory amino acid receptors in the 
vertebrate central nervous system, Pharmacol Rev, Jun, 41(2), pp.143-210. 
 
 - 68 - 
Conti, F., DeBiasi, S., Minelli, A., Rothstein, J. D., and Melone, M., 1998. EAAC1, a 
high-affinity glutamate tranporter, is localized to astrocytes and gabaergic neurons 
besides pyramidal cells in the rat cerebral cortex, Cerebral Cortex, Mar, 8(2), pp.108-116. 
 
Conti, F. and Weinberg, R. J., 1999. Shaping excitation at glutamatergic synapses, Trends 
in Neurosciences, 22, (10), pp. 451-458. 
 
Crino, P.B., Jin, H., Shumate, M.D., Robinson, M.B., Coulter, D.A., and Brookskayal, 
A.R., 2002. Increased expression of the neuronal glutamate transporter (EAAT3/EAAC1) 
in hippocampal and neocortical epilepsy, Epilepsia, 43, pp. 211-218. 
 
Danbolt, N.C., Storm-Mathisen, J., and Kanner, B.I., 1992. An [Na+ + K+] coupled L-
glutamate transporter purified from rat brain is located in glial cell processes, 
Neuroscience, 51, pp. 295-310. 
 
Danbolt, N.C., Lehre, K.P., Dehnes, Y., Chaudhry, F.A., and Levy, L.M., 1998. 
Localization of transporters using transporter-specific antibodies, Methods in 
Enzymology, 296, pp. 388-407. 
 
Danbolt, N.C., 2001. Glutamate uptake, Progress in Neurobiology, 65, pp. 1-105. 
 
de Lanerolle, N.C., Eid, T., von Campe, G., Kovacs, I., Spencer, D.D., and Brines, M., 
1998. Glutamate receptor subunits GluR1 and GluR2/3 distribution shows reorganization 
in the human epileptogenic hippocampus, European Journal of Neuroscience, 10, pp. 
1687-1703. 
 
de Lanerolle, N.C., Kim, J.H., Williamson, A., Spencer, S.S., Zaveri, H.P., Eid, T., and 
Spencer, D.D., 2003. A retrospective analysis of hippocampal pathology in human 
temporal lobe epilepsy: evidence for distinctive patient subcategories, Epilepsia, 44, pp. 
677-687. 
 
 - 69 - 
de Lanerolle, N.C. and Lee, T.S., 2005. New facets of the neuropathology and molecular 
profile of human temporal lobe epilepsy, Epilepsy and Behavior, 7, pp. 190-203. 
 
de Lanerolle, N.C., Williamson, A., Meredith, C., Kim, J.H., Tabuteau, H., Spencer, 
D.D., and Brines, M.L., 1997. Dynorphin and the kappa 1 ligand, Epilepsy Research, 28, 
pp. 189-205. 
 
de Lanerolle, N.C., Kim, J.H., Brines, M.L., 1994. Cellular and molecular alterations in 
partial epilepsy, Clinical Neuroscience, 2, pp. 64-81. 
 
Dehnes, Y., Chaudhry, F.A., Ullensvang, K., Lehre, K.P., Storm-Mathisen, J., Danbolt, 
N.C., 1998. The glutamate transporter EAAT4 in rat cerebellar Purkinje cells: a 
glutamate-gated chloride channel concentrated near the synapse in parts of the dendritic 
membrane facing astroglia, Journal of Neuroscience, 18, pp. 3606-3619. 
 
Derouiche, A., Rauen, T., 1995. Coincidence of L-glutamate/L-aspartate transporter 
(GLAST) and glutamine synthetase (GS) immunoreactions in retinal glia: evidence for 
coupling of GLAST and GS in transmitter clearance. Journal of Neuroscience Research, 
42, pp. 131-143. 
 
During, M.J. and Spencer, D.D., 1993. Extracellular hippocampal glutamate and 
spontaneous seizure in the conscious human brain, Lancet, 341, pp. 1607-1610. 
 
Eid, T., Thomas, M.J., Spencer, D.D., Runden-Pran, E., Lai, J.C., Malthankar, G.V., 
Kim, J.H., Danbolt, N.C., Ottersen, O.P., de Lanerolle, N.C., 2004. Loss of glutamine 
synthetase in the human epileptogenic hippocampus: possible mechanism for raised 
extracellular glutamate in mesial temporal lobe epilepsy, Lancet, 363(9402), pp. 28-37. 
 
Eliasof, S., Arriza, J.L., Leighton, B.H., Kavanaugh, M.P., Amara, S.G., 1998. Excitatory 
amino acid transporters of the salamander retina: identification, localization, and 
function, Journal of Neuroscience, 18, pp. 698-712. 
 - 70 - 
 
Engel, J.Jr., 2001. Mesial temporal lobe epilepsy: what have we learned?, Neuroscientist, 
7, pp. 340–352.  
 
Fairman, W.A., Vandenberg, R.J., Arriza, J.L., Kavanaugh, M.P., and Amara, S.G., 1995. 
An excitatory amino-acid transporter with properties of a ligand-gated chloride channel, 
Nature, 375, pp. 599-603. 
 
Ferrie, C.D., Bird, S., Tilling, K., Maisey, M.N., Chapman, A.G., and Robinson, R.O., 
1999. Plasma amino acids in childhood epileptic encephalopathies, Epilepsy Research, 
34, pp. 221-229. 
 
Fonnum, F., 1984, Glutamate: a neurotransmitter in mammalian brain, Journal of 
Neurochemistry, 42, pp. 1-11. 
 
Furuta, A., Rothstein, I.D., Martin, L.J., 1997a. Glutamate transporter protein subtypes 
are expressed differentially during rat CNS development, Journal of Neuroscience, 17, 
pp. 8363-8375. 
 
Ghijsen, W.E.J.M., Belo, A.I.D.A., Zuiderwijk, M., and da Silva, F.H.L., 1999. 
Compensatory change in EAAC1 glutamate transporter in rat hippocampus CA1 region 
during kindling epileptogenesis, Neuroscience Letters, 276, pp. 157-160.  
 
Gjessing, J., Renal failure in acute pancreatitis, 1972. British Medical Journal, Nov 11, 
4(836), pp. 359-60. 
 
Gorter, J.A., Van Vliet, E.A., Proper, E.A., De Graan, P.N.E., Ghijsen, W.E.J.M., Da 
Silva, F.H.L., and Aronica, E., 2002.  Glutamate transporters alterations in the 
 - 71 - 
reorganizing dentate gyrus are associated with progressive seizure activity in chronic 
epileptic rats, Journal of Comparative Neurology, 442, pp. 365-377. 
 
Hamberger, A., Berthold, C-H., Karlsson, B., Lehmann, A. and Nyström, B., 1983. 
Extracellular GABA, glutamate and glutamine in vivo - perfusion-dialysis of rabbit 
hippocampus, Neurology and Neurobiology, 7, pp. 473-492. 
 
Hamberger, A. and Nyström, B., 1984. Extra- and intracellular amino acids in the 
hippocampus during development of hepatic encephalopathy, Neurochemical Research; 
9, (9): 1181-1192. 
 
Harada, T., Harada, C., Watanabe, M., Inoue, Y., Sakagawa, T., Nakayama, N., Sasaki, 
S., Okuyama, S., Watase, K., Wada, K., Tanaka, K., 1998. Functions of the two 
glutamate transporters GLAST and GLT-1 in the retina, Proc Natl Acad Sei, U S A, 95, 
pp. 4663-4666. 
 
Haugeto, Ø., Ullensvang, K., Levy, L.M., Chaudhry, F.A., Honoré, T., Nielsen, M., 
Lehre, K.P., Danbolt, N.C.,1996. Brain glutamate transporter proteins form 
homomultimers. Journal of Biological Chemistry, 271, pp. 27715-27722. 
 
Hauser, W.A., Kurland, L.T., 1975. The epidemiology of epilepsy in Rochester, 
Minnesota, 1935 through 1967, Epilepsia., 16(1), pp. 1-66. 
 
Headley, P.M. and Grillner, S., 1990. Excitatory amino acids and synaptic transmission: 
the evidence for a physiological function, Trends Pharmacol Sci, May, 11(5), pp. 205-
211. 
 
Hsu, S., Raine, L., Fanger, H., 1981. The use of avidin-biotin-peroxidase complex (ABC) 
in immunoperoxidase techinques: a comparison between ABC and unlabeled antibody 
(PAP) procedures, Journal of Histochemistry and Cytochemistry, 29, pp. 577-580. 
 
 - 72 - 
Hösli, E., Krogsgaard-Larsen, P., and Hösli, L., 1983. Binding sites for the glutamate-
analogue [3H]AMPA in cultured rat brainstem and spinal cord, Brain Research, 268, 
pp.177-180. 
 
Ingram, E.M., Wiseman, J.W., Tessler, S., and Emson, P.C., 2001. Reduction of glial 
glutamate transporters in the parietal cortex and hippocampus of the EL mouse, Journal 
of Neurochemistry, 79, pp. 564-575. 
 
Janjua, N.A., Itano, T., Kugoh, T., Hosokawa, K., Nakano, M., Matsui, H., Hatase, O., 
1992. Familial increase in plasma glutamic acid in epilepsy, Epilepsy Research., 11(1), 
pp. 37-44. 
 
Kanai, Y. and Hediger, M.A., 1992. Primary structure and functional characterization of 
a high-affinity glutamate transporter, Nature, 360, pp. 467-471. 
 
Kanner, B. I. and Sharon, I., 1978. Active transport of L-glutamate by membrane vesicles 
isolated from rat brain, Biochemistry, Sep 19, 17(19), pp. 3949-3953. 
 
Kim, J.H., 2001. Pathology of epilepsy, Experimental and Molecular Pathology, 70(3), 
pp. 345-367. 
 
Klöckner, U., Storck, T., Conradt, M., and Stoffel, W., 1993. Electrogenic L-glutamate 
uptake in Xenopus laevis oocytes expressing a cloned rat brain L-glutamate/L-aspartate 
transporter (GLAST-1), Journal of Biological Chemistry, Jul 15, 268(20), pp. 14594-
14596. 
 
Kugler, P. and Schmitt, A., 1999. Glutamate transporter EAAC1 is expressed in neurons 
and glial cells in the rat nervous system, Glia, Aug, 27(2), pp.129-142. 
 
 - 73 - 
Laemmli, U.K., 1970. Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4, Nature, 227, pp. 680-685. 
 
Lehre, K.P., Levy, L.M., Ottersen, O.P., Storm-Mathisen, J., and Danbolt, N.C., 1995. 
Differential expression of two glial glutamate transporters in the rat brain: quantitative 
and immunocytochemical observations, Journal of Neuroscience , 15, pp. 1835-1853. 
 
Lehre, K.P., Davanger, S., Danbolt, N.C., 1997. Localization of the glutamate transporter 
protein GLAST in rat retina. Brain Research, 744, pp. 129-137. 
 
Lehre, K.P., Danbolt, N.C., 1998. The Number of Glutamate Transporter Subtype 
Molecules at Glutamatergic Synapses: Chemical and Stereological Quantification in 
Young Adult Rat Brain, Journal of Neuroscience, 18, pp. 8751-8757. 
 
Levy, L.M., Lehre, K.P., Rolstad, B., and Danbolt, N.C., 1993. A monoclonal antibody 
raised against an [Na+ - K+]coupled L- glutamate transporter purified from rat brain 
confirms glial cell localization, FEBS Letters, 317, pp. 79-84. 
 
Levy, L.M., Attwell, D., Hoover, F., Ash, J.F., Bjoras, M., and Danbolt, N.C., 1998. 
Inducible expression of the GLT-1 glutamate transporter in a CHO cell line selected for 
low endogenous glutamate uptake, FEBS Letters, Feb 6, 422(3), pp. 339-342. 
 
Lorente de Nó, R., 1934. Studies on the structure of the cerebral cortex: II continuation of 
the study of the ammonic system, Journal of Psychology and Neurology (Leipzig), 46, 
pp. 113-77. 
 
Martin, L.J., Brambrink, A.M., Lehmann, C., Portera-Cailliau, C., Koehler, R., Rothstein, 
J., Traystman, R.J., 1997. Hypoxia-ischemia causes abnormalities in glutamate 
transporters and death of astroglia and neurons in newbom striatum, Annals of 
Neurology, 42, pp. 335-348. 
 
 - 74 - 
Mathern, G.W., Mendoza, D., Lozada, A., Pretorius, J.K., Dehnes, Y., Danbolt, N.C., 
Nelson, N., Leite, J.P., and Chimelli, L., 1999. Hippocampal GABA and glutamate 
transporter immunoreactivity in patients with temporal lobe epilepsy, Neurology, 52, pp. 
453-472. 
 
Mathern, G.W., Babb, T.L., Armstrong, D.L., 1997. Hippocampal sclerosis, In: Engel, J., 
Pedley, T.A., eds. Epilepsy: a comprehensive textbook, Lippincott-Raven, Philadelphia, 
pp. 133-155. 
 
Meldrum, B.S. and Bruton, C.J., 1992. Epilepsy. In: J.H. Adams and L.W. Duchen, eds, 
Greenfield's Neuropathology, Oxford University Press, New York, pp. 1246–1283. 
 
Meldrum, B.S., 1994. The role of glutamate in epilepsy and other CNS disorders, 
Neurology, 44, pp. 14-23. 
 
Meldrum, B.S., Akbar, M.T., and Chapman, A.G., 1999. Glutamate receptors and 
transporters in genetic and acquired models of epilepsy, Epilepsy Research, 36, pp. 189-
204. 
 
Mennerick, S., Dhond, R.P., Benz, A., Xu, W., Rothstein, I.D., Danbolt, N.C., Isenberg, 
K.E., Zorumski, C.F., 1998. Neuronal expression of the glutamate transporter GLT-l in 
hippocampal microcultures, Journal of Neuroscience, 18, pp. 4490-4499. 
 
Milton, I.D., Banner, S.J., Ince, P.G., Piggott, N.H., Fray, A.E., Thatcher, N., Horne, 
C.H.W., and Shaw, P.J., 1997. Expression of the glial glutamate transporter EAAT2 in 
the human CNS: an immunohistochemical study, Molecular Brain Research, 52, pp. 17-
31. 
 
 - 75 - 
Musshoff, U., Schünke, U., Köhling, R., and Speckmann, E.J., 2000. Alternative splicing 
of the NMDAR1 glutamate receptor subunit in human temporal lobe epilepsy, Molecular 
Brain Research, 76, pp. 377-384. 
 
Nadler, J.V., 2003. The recurrent mossy fiber pathway of the epileptic brain, 
Neurochemistry Research, 28, pp. 1649–1658.  
 
Nagao, S., Kwak, S., and Kanazawa, I., 1997. EAAT4, a glutamate transporter with 
properties of a chloride channel, is predominantly localized in Purkinje cell dendrites, and 
forms parasagittal compartments in rat cerebellum, Neuroscience, 78, pp. 929-933. 
 
Nonaka, M., Kohmura, E., Yamashita, T., Shimada, S., Tanaka, K., Yoshimine, T., 
Tohyama, M., and Hayakawa, T., 1998. Erratum to: Increased transcription of glutamate-
aspartate transporter (GLAST/glut-1) mRNA following kainic acid-induced limbic 
seizure [vol 55 (1998), pp. 54-60], Molecular Brain Research, 60, p. 310. 
 
Northington, F.J., Traystman, R.J., Koehler, R.C., Rothstein, I.D., Martin, L.J., 1998. 
Regional and cellular expression of glial (GLTl) and neuronal (EAAC1) glutamate 
transporter proteins in ovine fetal brain. Neuroscience, 85, pp. 1183-1194. 
 
Olney, J.W., 1978. Neurotoxicity of exitatory amino acids, In: McGeer, E.G., Olney, 
J.W., McGeer, P.L., eds. Kaini acid as a tool in neurobiology, Raven Press, New York, 
pp. 37-70. 
 
Olney, J.W., Collins, R.C., Sloviter, R.S., 1986. Excitotoxic mechanisms of epileptic 
brain damage, Advances in Neurology, 44, pp. 857-77. 
 
Ottersen, O.P. and Storm-Mathisen, J., 1984. Neurons containing or accumulating 
transmitter amino acids. Bjorklund, A., Hökfelt, T., and Kuhar, M.J., Handbook of 
 - 76 - 
Chemical Neuroanatomy: Classical Transmitters and transmitter receptors in the CNS. 
Elsevier Science Publishers B.V., Amsterdam, 3, Part II, pp.141-246.  
 
Ottersen, O.P., Laake, J.H., Reichelt, W., Haug, F.M. and Torp, R., 1996. Ischemic 
disruption of glutamate homeostasis in brain: quantitative immunocytochemical analysis, 
Journal of Chemical Neuroanatomy, 12, pp. 1-14. 
 
Pines, G., Danbolt, N.C., Bjørås, M., Zhang, Y., Bendahan, A., Eide, L., Koepsell, H., 
Storm-Mathisen, J., Seeberg, E., and Kanner, B.I., 1992. Cloning and expression of a rat 
brain L-glutamate transporter, Nature, 360, pp. 464-467. 
 
Proper, E.A., Hoogland, G., Kappen, S.M., Jansen, G.H., Rensen, M.G., Schrama, L.H., 
van Veelen, C.W., van Rijen, P.C., van Nieuwenhuizen, O., Gispen, W.H., and de Graan, 
P.N., 2002. Distribution of glutamate transporters in the hippocampus of patients with 
pharmaco-resistant temporal lobe epilepsy, Brain, 125, pp. 32-43. 
 
Rauen, T., Kanner, B.I., 1994. Localization of the glutamate transporter GLT-1 in rat and 
macaque monkey retinae, Neuroscience Letters, 169, pp. 137-140. 
 
Rauen, T., Rothstein, I.D., Wassle, H., 1996. Differential expression of three glutamate 
transporter subtypes in the rat retina, Cell Tissue Research, 286, pp. 325-336. 
 
Roskoski, R.Jr., 1979. Net uptake of aspartate by a high-affinity rat cortical synaptosomal 
transport system. Brain Research, Jan 5, 160(1), pp. 85-93. 
 
Rothstein, J.D., Martin, L., Levey, A.I., Dykes-Hoberg, M., Jin, L., Wu, D., Nash, N., 
and Kuncl, R.W., 1994. Localization of neuronal and glial glutamate transporters, 
Neuron, 13, pp. 713-725. 
 
Samuelsson, C., Kumlien, E., Flink, R., Lindholm, D., and Ronne-Engstrom, E., 2000.  
Decreased cortical levels of astrocytic glutamate transport protein GLT-1 in a rat model 
 - 77 - 
of posttraumatic epilepsy, Neuroscience Letters, 289, pp. 185-188. 
 
Sarantis, M. and Attwell, D., 1990, Glutamate uptake in mammalian retinal glia is 
voltage- and potassium-dependent, Brain Research, May 21, 516(2), pp. 322-325. 
 
Schmitt, A., Asan, E., Puschel, B., Jons, T., Kugler, P., 1996. Expression of the glutamate 
transporter GLT1 in neural cells of the rat central nervous system: non-radioactive in situ 
hybridization and comparative immunocytochemistry, Neuroscience, 71, pp. 989-1004. 
 
Schmitt, A., Asan, E., Puschel, B., Kugler, P., 1997. Cellular and regional distribution of 
the glutamate transporter GLAST in the CNS of rats: nonradioactive in situ hybridization 
and comparative immunocytochemistry, Journal of Neuroscience, 17, pp. 1-10. 
 
Semah, F., Picot, M.C., Adam, C., Broglin, D., Arzimanoglou, A., Bazin, B., Cavalcanti, 
D. and Baulac, M., 1998. Is the underlying cause of epilepsy a major prognostic factor for 
recurrence?, Neurology, 51, pp. 1256–1262.  
 
Shelton, M.K. and McCarthy, K.D., 1999. Mature hippocampal astrocytes exhibit 
functional metabotropic and ionotropic glutamate receptors in situ, Glia, Mar, 26(1), pp. 
1-11. 
 
Simantov, R., Crispino, M., Hoc, W., Broutman, G., Tocco, G., Rothstein, J.D., and 
Baudry, M., 1999. Changes in expression of neuronal and glial glutamate transporters in 
rat hippocampus following kainate-induced seizure activity, Molecular Brain Research, 
65, pp. 112-123. 
 
Sloviter, R.S., 1992. Possible functional consequences of synaptic reorganization in the 
dentate gyrus of kainate-treated rats, Neuroscience Letters, 137, pp. 91–96.  
 - 78 - 
 
Sloviter, R.S., 2005. The neurobiology of temporal lobe epilepsy: too much information, 
not enough knowledge, Comptes Rendus Biologies, 328, pp. 143-153.  
 
Sommer W., 1880. Erkrankung des Ammonshorns as aetiologisches Momnet der 
Epilepsie, Archiv fur Psychiatrie und Nervenkrankheiten, 10, pp. 631-675. 
 
Steinhauser, C. and Gallo, V., 1996. News on glutamate receptors in glial cells, Trends in 
Neurosciences, 19, (8), pp. 339-345. 
 
Spencer, D.D., Spencer, S.S., Mattson, R.H., Williamson, P.D., Novelly, R.A., 1984. 
Access to the posterior medial temporal lobe structures in the surgical treatment of 
temporal lobe epilepsy, Neurosurgery, 15(5), pp. 667-671. 
 
Storck, T., Schulte, S., Hofmann, K., and Stoffel, W., 1992. Structure, expression, and 
functional analysis of a Na+-dependent glutamate/aspartate transporter from rat brain, 
Proceedings of the National Academy of Sciences of the United States of America, 89, 
pp. 10955-10959. 
 
Storm-Mathisen, J., Danbolt, N.C., Rothe, F., Torp, R., Zhang, N., Aas, J.E., Kanner, 
B.I., Langmoen, I. and Ottersen, O.P., 1992. Ultrastructural immunocytochemical 
observations on the localization, metabolism and transport of glutamate in normal and 
ischemic brain tissue, Progress of Brain Research, 94, pp. 225-41. 
 
Szatkowski, M., Barbour, B., and Attwell, D., 1991. The potassium-dependence of 
excitatory amino acid transport: resolution of a paradox, Brain Research, Aug 2, 555(2), 
pp. 343-345. 
 
 - 79 - 
Tanaka, K., 1993. Cloning and expression of a glutamate transporter from mouse brain, 
Neuroscience Letters, 159, pp. 183-186. 
 
Tanaka, K., Watase, K., Manabe, T., Yamada, K., Watanabe, M., Takahashi, K., Iwama, 
H., Nishikawa, T., Ichihara, N., Hori, S., Takimoto, M., and Wada, K., 1997. Epilepsy 
and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1, 
Science, 276, pp. 1699-1702. 
 
Tauck, D.L. and Nadler, J.V., 1985. Evidence of functional mossy fiber sprouting in 
hippocampal formation of kainic acid treated rats, Journal of Neuroscience, 5, pp. 1016–
1022.  
 
Tessler, S., Danbolt, N.C., Faull, R.L.M., Storm-Mathisen, J., and Emson, P.C., 1999. 
Expression of the glutamate transporters in human temporal lobe epilepsy, Neuroscience, 
88, pp. 1083-1091. 
 
Torp, R., Danbolt, N.C., Babaie, E., Bjoras, M., Seeberg, E., Storm-Mathisen, J., 
Ottersen, O.P., 1994. Differentia1 expression of two glial glutamate transporters in the rat 
brain: an in situ hybridization study, European Journal of Neuroscience, 6, pp. 936-942. 
 
Torp, R., Hoover, F., Danbolt, N.C., Storm-Mathisen, J., Ottersen, O.P., 1997. 
Differential distribution of the glutamate transporters GLT1and rEAACl in rat cerebral 
cortex and thalamus: an in situ hybridization analysis, Anatomy and Embryology (Berl), 
195, pp. 317-326. 
 
Towbin, H., Staehelin, T., and Gordon, J., 1979. Electrophoretic transfer of proteins from 
polyacrylamide gels to nitrocellulose sheets: Procedure and some applications, 
Proceedings of the National Academy of Sciences of the United States of America, 76, 
pp. 4350-4354. 
 
 - 80 - 
Ueda, Y., Doi, T., Tokumaru, J., Yokoyama, H., Nakajima, A., Mitsuyama, Y., 
Ohyanishiguchi, H., Kamada, H., and Willmore, L.J., 2001. Collapse of extracellular 
glutamate regulation during epileptogenesis: down-regulation and functional failure of 
glutamate transporter function in rats with chronic seizures induced by kainic acid, 
Journal of Neurochemistry, 76, pp. 892-900. 
 
Ullensvang, K., Lehre, K.P., Storm-Mathisen, J., Danbolt, N.C., 1997. Differential 
developmental express ion of the two rat brain glutamate transporter proteins GLAST and 
GLT, European Journal of Neuroscience, 9, pp. 1646-1655. 
 
Van den Berg, C.J. and Garfinkel, D.A., 1971. A simulation study of brain compartments 
- metabolism of glutamate and related substances in mouse brain, Biochemical Journal, 
123, pp. 211-218. 
 
Williamson, A., Spencer, S.S., and Spencer, D.D., 1995. Depth electrode studies and 
intracellular dentate granule cell recordings in temporal lobe epilepsy. Annals of 
Neurology, Nov; 38(5), pp. 778-87. 
 
Yamada, K., Watanabe, M., Shibata, T., Tanaka, K., Wada, K., and Inoue, Y., 1996. 
EAAT4 is a post-synaptic glutamate transporter at Purkinje cell synapses, Neuroreport, 7, 
pp. 2013-2017. 
 
Yamada, K., Watanabe, M., Shibata, T., Nagashima, M., Tanaka, K., Inoue, Y., 1998. 
Glutamate transporter GLT-l is transiently localized on growing axons of the mouse 
spinal cord before establishing astrocytic expression, Journal of Neuroscience, 18, pp. 
706-713. 
 
Zerangue, N. and Kavanaugh, M.P., 1996. Flux coupling in a neuronal glutamate 
transporter, Nature, Oct 17, 383(6601), pp. 634-637. 
